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Background:  Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8) is the 
etiologic agent of Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD), and 
primary effusion lymphoma (PEL).  KSHV is a nonubiquitous herpesvirus (~3% in the 
general US population) that can cause significant morbidity and mortality among 
immunocompromised hosts.  However, routine surveillance of KSHV is lacking because 
diagnostic systems for viral identification are not of high enough sensitivity and 
specificity.  This research describes a novel KSHV serological algorithm which increases 
sensitivity and specificity of KSHV detection beyond what has been previously reported. 
Methods:  A novel KSHV assay algorithm based on a baculovirus-expressed LANA1-
GST fusion protein was used with previously described KSHV lytic antigen ELISAs.  
Initial assay evaluation was performed using 90 case sera from persons with AIDS- KS 
and 100 blood donor controls.  We identified two multi-antigen algorithms: one that 
maximized sensitivity and one that maximized specificity.  Sera from patients requiring 
bone-marrow transplantation, cadaveric renal transplant donors (CRTD), patients with 
systemic lupus erythematosus (SLE) and subjects with primary (PPH) and secondary 
pulmonary hypertension were obtained for KSHV testing.   
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Results:  The highly sensitive algorithm yielded a sensitivity of 96% and a specificity of 
94% and the highly specific algorithm a sensitivity of 93% and a specificity of 98%.    
Among CRTD, using the highly specific algorithm, overall seroprevalence was low at 
4.0% (2/50) and similar to blood donors (P=0.46; OR=1.4; CI=0.14, 7.9).  With the more 
specific algorithm, 8.0% (4/50) were infected compared to 6.4% (16/250) among blood 
donors (OR=1.3; CI=0.41,4.0; P=0.43).  Among subjects requiring bone marrow 
transplantation seroprevalence was 3.0% and 10.0% and did not differ from blood donors 
(OR=2.0; 95% CI=0.10,122.9; P=0.50).  Higher KSHV seroprevalence was observed 
among SLE patients using the specific algorithm (OR=6.0; 95% CI, 1.2-29.0) and the 
sensitive algorithm (OR=3.6; 95% CI, 1.1-12.2) though this is likely due to antigenic 
cross-reactivity as opposed to actual infection.  Among patients with PPH we found no 
evidence of KSHV infection (0/19). 
Conclusions: We used a systematic approach to standardize the assessment of KSHV 
infection rates and examined seroprevalence rates among high-risk populations of clinical 
interest.  KSHV is of public health importance because it leads to cancer in 
immunocompromised hosts.  Future studies of KSHV should focus on the cost-
effectiveness of implementing surveillance systems such as the one described here, which 
could potentially lead to a marked reduction in KSHV-associated morbidity and 
mortality. 
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1. Kaposi’s sarcoma-associated herpesvirus: Introduction 
 Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human 
herpesvirus 8 (HHV-8), is the most recently described human herpesvirus.  Discovered 
by Chang and Moore in 1994(100, 298), KSHV is a nonubiquitous herpesvirus which 
most often causes clinical manifestations among immunocompromised hosts.  In fact, 
early in the AIDS epidemic of the 1980’s, Kaposi’s sarcoma (KS), caused by KSHV, was 
the most common AIDS defining illness.   
 Though the morbidity and mortality associated with KSHV infection among 
immunocompromised hosts is substantial, routine surveillance of infection among these 
populations is lacking.  Currently, diagnostic systems for identifying KSHV infection are 
not of high enough sensitivity and specificity to be used in the clinical setting.  The 
following chapters describe the epidemiology and public health impact of KSHV 
infection among immunocompromised and immunocompentent hosts, as well as research 
describing a new algorithm for defining KSHV infection using established and novel 
serological assays.  In conclusion, the potential impact of the research is addressed with 
specific attention being paid to public health and epidemiology. 
1.1.  Clinical Manifestations 
 KSHV is known to be associated with three conditions; Kaposi’s sarcoma (KS), a 
blood vessel cancer, multicentric Castleman’s disease (MCD), a form of severe lymph 
node enlargement and primary effusion lymphoma (PEL), a cancer of the 
lymphocytes(295, 373).  In addition, case series suggest that KSHV may play a role in a 
newly described syndrome of bone marrow failure after transplantation(121, 258).  Of 
these, KSHV is suspected as the causal agent in each, though current evidence supports a 
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definitive causal role only with KS. Though other disease associations have been sought, 
no conclusive evidence exists to support a consistent relation between KSHV and any 
other disease or syndrome at this time.  Scientists have not ruled out KSHV as a co-factor 
in other disorders however, and many groups are actively pursuing other diseases which 
may be associated with the virus.   
 Of the diseases caused by KSHV, KS is most clinically important with an 
estimated annual incidence of 5 cases per 100,000 per year(307).  In the United States, 
KS is most common among homosexual men with AIDS.  However, due to 
improvements in AIDS therapies, KS incidence has been in decline among this 
population.  Historical data suggests that KS incidence is not in decline among other 
populations however, and in fact may be more common today than it was just 50 years 
ago. 
The current dogma is that among individuals without underlying 
immunosuppression KSHV is largely asymptomatic.  In a case-control study of HIV-
negative males, some acute non-specific symptoms such as diarrhea, fatigue, rash and 
lymphadenopathy were more common among those recently acquiring KSHV than 
among non-seroconverters(257, 314).  However, in actuality, little information exists as 
to the actual risk of KS among immunocompetent KSHV infected individuals(142).  
Long term follow-up studies conducted in such a population with appropriate matched 
controls have not been undertaken.  Additionally, cancer statistics data bases, such as the 
Surveillance Epidemiology and End Results (SEER) data base, do not stratify KS 
incidence and prevalence data by HIV infection status.  Therefore, accurately assessing 
the rate of KS among HIV uninfected individuals using national surveillance data is not 
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currently possible.  One assumption which has been made is that KS incidence in the US 
among HIV uninfected individuals has remained constant over the last 50 years and rates 
prior to the AIDS epidemic are reflective of current rates(43), though the accuracy of 
such an assumption is difficult to directly examine.   
 In general, the risk of acute measurable KSHV associated morbidity and mortality 
among the general population is likely low.  However, the long-term consequences of 
infection have not been explored.  Longitudinal studies which track survival, in addition 
to morbidity assumed to be directly unassociated with KSHV infection, are required to 
provide a definitive answer to the actual effects of KSHV infection among the general 
population.   
Though KSHV is associated with at least three diseases: Kaposi’s sarcoma (KS), 
body cavity-based lymphoma; and multicentric Castleman’s disease, (295, 373).  Other 
disease associations, including multiple myeloma, sarcoidosis, primary pulmonary 
hypertension(68, 110), and post-transplant skin cancers, have been suggested but these 
associations have either not been adequately confirmed or later refuted(122, 193, 225, 
240).  The following sections describe the known clinical syndromes in which KSHV is 
associated and discusses other diseases in which KSHV is now known not to play a role. 
1.1.1.  Kaposi’s Sarcoma 
 The most important clinical manifestation of KSHV infection is Kaposi’s sarcoma 
(KS).  Described in 1872 by Moritz Kaposi, KS is a neoplastic disorder first identified in 
five patients as an idiopathic multiple pigmented sarcoma of the skin.  Since that time 
four distinct epidemiologic forms of KS have been defined; classic KS, endemic KS, 
AIDS-KS, and iatrogenic KS.  KSHV is an etiologic co-factor in common to all forms of 
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KS, and the histological features of KS are indistinguishable between the clinical 
variants.   
KS  is a proliferative condition with lesions comprised of spindle cells 
surrounding vascular slits.  There are three distinct histologic stages of KS and include 
the patch, plaque, and nodular forms.  Though KS is most commonly localized to the 
skin, organ involvement can occur and is not uncommon in AIDS-KS. 
1.1.1.1.  Classic Kaposi’s Sarcoma 
 Classic KS presents as a disease of the feet and hands primarily among older men 
of Mediterranean and Jewish descent.  The male to female ratio of classic KS has been 
reported to be 15:1 (18, 133) with age of onset most common at greater than 50 years of 
age(120, 205, 368, 415) and rarely (4%-8%) prior to 30 years of age(42, 132, 175, 197, 
422).  The least aggressive form of KS, classic KS is a slow or non progressing disease 
that when even left untreated rarely invades the visceral compartments(211).  The mean 
survival of patients with classic KS is 10 to 15 years with cause of death generally 
attributed to an unrelated condition associated with age(106).   
Epidemiologically, classic KS has the highest incidence rates in Italy, Greece, and 
Israel(211) and even prior to the AIDS epidemic, rates of reported KS incidence began to 
rise.  Whether these observations were due to increased reporting, misdiagnosis, or were 
the result of an actual increase, population-based reporting of KS was notably elevated 
throughout Europe and Israel in the 1960’s and 1970’s(132, 197, 211, 212, 422).  In 
contrast, within the US, classic KS is rare with only an approximated 600 cases reported 
prior to 1950(282).  In a retrospective analysis performed by Biggar et al., the annual KS 
incidence prior to the AIDS epidemic was estimated to be 0.29 cases/100,000/year among 
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men and 0.07 cases/100,000/year among women(42).  Currently in the United States 
reporting of KS includes all forms, of which AIDS-KS is the majority, therefore accurate 
assements of rates of the classic form are unavailable, though it is still believed that 
classic KS in the Western hemisphere is extraordinarily rare. 
1.1.1.2.  Endemic Kaposi’s Sarcoma 
 Recognition of KS as a common cancer in parts of Africa became apparent in the 
literature of the 1950s.  Prior to the AIDS epidemic, KS was not uncommon and 
represented 9%-13% of all malignancies in Zaire and 3%-9% in Uganda(109, 205, 312, 
414).  Endemic KS has two epidemiologic sub-categories.  One form affects young 
adults, with mean age of onset at 35 years of age and a male to female ratio of 
approximately 15:1.  Survival rates among this group range from 5 to 8 years after 
diagnosis(410, 429).  The second form, which is higly aggressive and associated with 
high mortality, affects children with mean age of onset at 3 years of age and a male to 
female ratio of 3:1.  KS comprises 2%-10% of all cancers among children in central 
Africa(23, 105). 
 Studies of endemic KS are now difficult to perform in the setting of the African 
AIDS epidemic.  KS is currently the most common form of cancer in men and second 
most common cancer among adult women in much of central Africa.  An example of how 
the HIV epidemic confounds the true assessment of endemic KS can be shown in other 
changes observed in KS incidence since AIDS.  Namely, the male to female ratio has 
dramatically shifted to near parity with reported male to female ratios observed to be 2:1 
in 1996(393).  This observation is likely not due to differences in KSHV exposure status, 
as men and women have similar KSHV prevalence in Africa(281, 316).  Some have 
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hypothesized that hormonal dynamics may play a role in the development of KS though 
currently no direct evidence exists to support firm conclusions(316).   
Though highly active anti-retroviral therapy (HAART) has reduced the incidence 
of KS in the Western world, incidence of KS in Africa is still common and likely the 
result of untreated HIV infection(106).  As routine HAART therapy becomes more 
readily available, especially among children, it is assumed that KS prevalence rates will 
likely begin to decline in Africa.  However, with the extraordinarily high rate of HIV and 
KSHV viral endemicity the problem of KS in Africa will likely not soon be under 
control. 
1.1.1.3.  AIDS-associated Kaposi’s Sarcoma 
 Prior to the AIDS epidemic, KS in the US was very rare with an estimated 2 to 6 
cases per million individuals per year annual incidence(206, 312, 367, 368).  However, in 
the summer of 1981 large numbers of homosexual men in New York and California 
began presenting to hospitals with the distinctive skin lesions of KS(96, 167, 206).  It 
soon became apparent that a number of rare opportunistic infections were suddenly of 
epidemic proportions.   
The incidence rate of KS among HIV-infected individuals has been reported to be 
several thousand folds higher than the general population(211).  Among homosexual men 
with HIV infection at the beginning of the AIDS epidemic the risk of developing KS 
approached 50%(44, 45), and approximately 40% of patients who received a diagnosis of 
AIDS presented with KS.  More recently, it has been noted that among KSHV/HIV 
coinfected males the 10 year risk of KS is 39%-50%(275, 310).   
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Overall annual KS incidence peaked at 10.2 per 100,000 in white males in 1988 
and 10.5 per 100,000 in black males in 1992 (Figure 1-1). 
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Figure 1 -1.  SEER Incidence Age-Adjusted Rates of Kaposi's Sarcoma 
1973-2000 
Nearly half of HIV-positive males are infected with KSHV, yet, as Figure 1-1 shows, KS 
rates among this group have fallen dramatically in recent years.  Some of this fall can be 
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attributed to improvements in the overall health of HIV-positive individuals due to HIV-
targeted immuno-reconstitution therapies such as HAART, introduced in the mid 
1990s(307).  Many studies have shown that HAART, particularly a regimen containing at 
least one protease inhibitor, is effective in reducing skin lesions and prolonging life in 
AIDS-KS patients(52, 245, 408).  Other reasons for the noted decline in KS likely 
include an expanded definition of AIDS-defining criteria, decreased reporting of minor 
dermatological cases and increased use of safe-sex practices associated with HIV 
prevention campaigns.  Though KS incidence has steadily declined over the last decade, 
it is still the most common neoplasm affecting people with HIV today(4, 78).   
Table 1-1 presents the most recent rates of KS observed in the US.  Overall rates 
are higher in the southern US compared to the rest of the country.  Similar geographical 
patterns exist for other sexually transmitted infectious diseases.  However, this 
geographical pattern cannot fully account for the increased incidence of KS observed in 
some locations such as the District of Columbia.  A complete understanding of the 
geographic distribution of KS in the US is not possible at this time though it is likely that 
reporting practices differ and may accout for some of the variability associated with 
incidence data. 
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Table 1-1.  Age-adjusted invasive Kaposi’s Sarcoma incidence rates and 95% confidence 
intervals by US census region and division, state and metropolitan area, all races.   
 
Area Male 
 
United States 
 
0.9 (0.8-0.9) 
 
Northeast 
        Massachusetts 
0.7 (0.5-1.0) 
0.9 (0.6-1.3) 
 
Middle Atlantic 
        New Jersey 
        New York 
        Pennsylvania 
 
1.2 (1.1-1.4) 
1.0 (0.7-1.4) 
1.6 (1.3-1.9) 
0.8 (0.6-1.1) 
Midwest 
    East North Central 
        Michigan 
            Detroit 
    West North Central 
              
0.4 (0.4-0.5) 
0.4 (0.3-0.5) 
0.5 (0.3-0.8) 
1.2 (0.7-1.8) 
0.4 (0.3-0.6) 
 
South 
    South Atlantic 
        District of Columbia 
        Florida 
        Georgia 
            Atlanta 
    West South Central 
        Louisiana 
        Texas 
 
 
 
5.3 (3.0-9.1) 
1.3 (1.0-1.5) 
1.3 (1.0-1.7) 
2.9 (2.1-4.3) 
0.8 (0.7-1.0) 
1.1 (0.7-1.8) 
0.8 (0.6-1.0) 
West 
    Mountain 
    Pacific 
        California 
            San Francisco-Oakland 
            Los Angeles 
        Washington 
            Seattle-Puget Sound 
 
1.1 (1.0-1.3) 
0.6 (0.4-0.8) 
1.4 (1.2-1.5) 
1.5 (1.4-1.8) 
2.8 (2.1-3.7) 
2.3 (1.9-2.8) 
0.9 (0.6-1.4) 
1.0 (0.6-1.6) 
Note:  Rates are per 100,000 and are age-adjusted to 2000 US standard population.  Rates 
cover approximately 92% of the US population.  Data from US cancer statistics 2004 report(424). 
 
In addition to the noted decreasing rates of KS, survival rates among patients with 
KS have increased.  In contrast to classic KS, AIDS-KS is highly aggressive and life-
threatening visceral and mucosal involvement is common.  In a postmortem study by 
Friedman et al., 77% of patients with AIDS-KS showed signs of visceral involvement at 
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autopsy(168).  Lemlich et al. found, at autopsy, that among AIDS-KS patients with no 
visible skin lesions that 29% had visceral involvement(248).  In the 1980’s KS prognosis 
was poor, though through the use of HAART, survival has dramatically improved to rates 
approximately half that observed prior to the AIDS epidemic (Figure 1-2)(307).    
Figure 1-2. SEER 5-Year Kaposi's Sarcoma Relative 
Survival Rates by Year of Diagnosis
Year of Diagnosis
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Figure 1-2. SEER 5-Year Kaposi's Sarcoma Relative Survival Rates by Year of 
Diagnosis  Note: Data from National Cancer Institute(363). 
 
Two factors associated with the development and progression of KS are high 
antilytic KSHV antibody titers and detection of KSHV DNA in peripheral blood(157, 
158, 161, 403).  Observations in mice models suggest inflammatory cytokines (IC) 
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trigger a cascade of events that lead to the genesis of KS lesions.  Experimental studies 
suggest that IC upregulation stimulates KSHV reactivation in circulating cells resulting in 
viral spread and dissemination in tissues(158, 160, 161).  KSHV viral dissemination 
causes an induction of the host immune response, but the full significance of the immune 
response is currently unknown.   
If ongoing viral activity is necessary for KS development, then the KSHV specific 
antibody response may play an important role in preventing KS.  However, because mean 
titers are usually higher in persons with KS, it is not clear that a KSHV antibody response 
is protective against KS.  Furthermore, in some studies CD4+ and CD8+ T cells and 
natural killer cells appeared ineffective in clearing KSHV infected cells from 
circulation(159, 403).  If KS development is due to the inability of the immune response 
to clear viral DNA in circulating cells, then high antibody titers would presumably not be 
protective against KS disease development and progression.  However, these 
observations may also be the result of an ecological fallacy(239, 241).  
Markers used to assess the severity of HIV/AIDS disease have been shown to be 
useful in assessing KS disease progression.   HIV viral load is associated with KSHV 
viremia(417) and is strongly associated with the severity of KS disease.  Lower CD4 
lymphocyte counts contribute to increased KS tumor burden and decreased survival times 
in patients with KS(52, 74, 408).  CD8+ T cell expansion and increased levels of 
inflammatory cytokines appear to be factors required for KS initiation(157).  These 
indicators of immune function, commonly used to assess HIV/AIDS disease stage, may 
be useful benchmarks for monitoring and predicting KS disease stage and progression.   
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Treatment 
Though treatment of the underlying immunodeficiency is likely the best and least 
invasive course of treatment for AIDS-KS(447), other treatment options exist and are 
routinely used.  Local treatments such as cryo, laser and excisional surgery have been 
used in the past, though primarily for cosmetic treatment and not for systemic 
management of the disease(25).  Chemotherapeutic agents such as doxorubicin and 
paclitaxel have shown to reduce lesion size(402, 435) though unacceptable toxicity and 
KS recurrence upon cessation are not uncommon(423).   
A number of experimental treatments are still under active study including 
treatment with thalidomide(445) and retinoids(5, 50).  Antiviral therapy has shown the 
most efficacy for KS treatment.  In epidemiology studies and clinical trials, anti-
herpesviral agents such as foscarnet and ganciclovir have shown reductions in relative 
risk of developing KS, though use in treatment of established KS is still controversial(25, 
57).  In conclusion, as with other types of KS, AIDS-KS is best treated through 
management of a patient’s underlying immunosuppression especially through the use of 
HAART(95). 
1.1.1.4.  Iatrogenic Kaposi’s Sarcoma 
In North America, few studies have been conducted to assess KS incidence in 
transplant recipients.  In Canada, KS was observed in 0.6% of solid organ recipients and 
0.1% of renal allograft recipients(126, 388).  In the United States, surveillance data 
reported to the United Network for Organ Sharing (UNOS) show that 0.03% of transplant 
recipients were diagnosed with KS between 1988 and 2002 (Table 1-2).  Of all cases of 
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post-transplant malignancy reported from 1968 to 1995 to the Cincinnati transplant tumor 
registry (CTTR),  KS comprised 4.1%(338).          
Table 1-2. Rates of KS reported to UNOS by transplanted organ 
 
Organ 
All 
Transplants 
1988-2002 
KS in 
recipients
Percent of recipients 
diagnosed with KS 
1988-2002 
Heart-Lung 799 0 0.00 
Heart 32514 14 0.04 
Intestine 697 0 0.00 
Kidney 169252 46 0.03 
Kidney-
Pancreas 10574 1 0.01 
Liver 56678 11 0.02 
Lung 10098 3 0.03 
Pancreas 3130 0 0.00 
Total 283742 75 0.03 
Note: Data provided by the United Network for Organ Sharing (UNOS)(425). 
 
Current estimates of KS incidence in transplant recipients are derived primarily 
from two sources; retrospective studies which utilize national cancer registry data and 
retrospective studies which evaluate KS incidence through a process of institutional chart 
review of patients who have undergone organ transplantation. Both methods of 
ascertaining KS incidence are likely to underestimate the true rates. However, based upon 
these studies, in most parts of the world KS is likely to occur in less than one or two 
percent of all transplant recipients (Table 1-3)(425).   
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  Table 1-3. Reported rates of Kaposi sarcoma among transplant recipients 
 
Reference 
 
Year 
Country and 
City/Region 
 
No. 
 
% 
 
Total 
 
Population 
 
Shepard et al.(388) 
 
1997 
 
Toronto, Canada 
 
12 
 
0.57 
 
2099 
 
Heart/Lung/Liver/Kidney 
Delorme et al.(126) 2003 Québec, Canada  1 0.09 1070 Kidney recipients 
Webb et al.(433) 1997 London, England  4 0.31 1304 Kidney recipients 
Emond et al.(149) 2002 Paris, France  1 0.67 150 Heart recipients 
Francés et al.(165) 2000 Paris, France  9 2.3 400 Kidney recipients 
Marcelin et al.(268) 2004 Paris, France  2 1.6 122 Liver recipients 
Touraine et al. 1996 Lyon France  0.48 2500 Kidney recipients 
Farge et al.(162) 1993 Ile de France  0.45 6229 Kidney recipients 
Sheldon et al.(387) 2000 Brussels, Belgium 0 0 200 Kidney recipients 
Behrend et al.(31) 1997 Hanover Germany 1 0.07 1497 Kidney recipients 
Mitxelena et al.(290) 2003 Bilbao, Spain  6 0.49 1230 Kidney recipients 
Gomez et al.(181) 1997 Madrid, Spain  3 0.5 609 Kidney recipients 
Anaya et al.(12) 2003 Madrid, Spain  5 0.24 2121 Kidney recipients 
Portillo Martin(345)  1992 Santander, Spain  1 0.23 431 Kidney recipients 
Zavos et al.(450) 2003 Athens, Greece  18 1.7 1055 Kidney recipients 
Montagnino(293) 1996 Milan, Italy  13 1.5 854 Kidney recipients 
Busnach et al.(70) 2001 Milan, Italy  2 0.4 499 Kidney recipients 
Cardillo et al.(82) 2001 Northern Italy  19 0.84 2261 Heart recipients 
Pedotti et al.(331) 2003 Italy  39 1.1 3521 Kidney recipients 
Lesnoni La Parola et 
al.(250) 
1997 Rome, Italy  10 3.3 302 Kidney recipients 
Cattani et al.(94) 2001 Rome, Italy  7 4.0 175 Kidney recipients 
Andreoni et al.(15) 2001 Rome, Italy  4 3.1 130 Kidney and Liver 
recipients 
Sheil et al.(386) 1987 N.Z./Australia 7 0.17 4241 Kidney recipients 
Sheil et al.(385) 1997 N.Z./Australia 17 0.21 7909 Kidney recipients 
Kim et al.(230) 1998 Seoul, Korea  5 0.3 1600 Kidney recipients 
Ecder et al.(146) 1998 Istanbul, Turkey  17 3.1 557 Kidney recipients 
Arican et al.(19) 2001 Ankara, Turkey  10 1.0 954 Kidney recipients 
Karakayali (221) 1999 Ankara, Turkey  8 0.69 1167 Kidney recipients 
Shmueli et al.(389) 1989 Petah Tiqva, Israel  8 2.4 330 Kidney recipients 
Qunibi et al.(348) 1993 Riyadh, Saudi Arabia  4.1 630 Kidney recipients 
Askari et al.(22) 1999 Karachi, Pakistan  6 0.95 630 Kidney recipients 
Al-Mousawi(8) 2001 Kuwait City, Kuwait  9 1.1 800 Kidney recipients 
Einollahi (147) 2001 Tehran, Iran  13 0.74 1750 Kidney recipients 
Lessan-Peze(251) 2001 Tehran, Iran  18 0.88 2050 Kidney recipients 
Margolius (271) 1994 Johannesburg, S.A.   0.5 989 Kidney recipients 
 
Significant morbidity and mortality are associated with a diagnosis of KS among 
transplant recipients.  In the Cincinnati transplant tumor registry, 143 (40.2%) of 356 
patients with KS had visceral involvement and 61 (17.1%) of 356 had KS listed as their 
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cause of death (338).  Although the reduction or cessation of immunosuppressive 
treatment can lead to the complete remission of KS, among patients undergoing 
remission 65% had graft loss or impaired function, compared to 21% of the overall 
population of transplant recipients(425).  In addition, patients with KS in remission are at 
increased risk of recurrence(138). 
In a recent report of liver transplant recipients in France, 100% of KSHV negative 
recipients who received a KSHV-infected allograft seroconverted within 6 months post-
transplantation.  Of those, 50% developed Kaposi’s sarcoma and died of multiorgan 
failure within 1 year post-transplantation (268).  Among patients KSHV seropositive 
prior to transplantation none had developed KSHV related illness at two years of follow-
up.  This report suggests denovo infection resulting from infected organs may present 
greater morbidity and mortality than KS acquired from KSHV reactivation in 
seropositive patients, an observation that appears to also be true for cytomegalovirus(53, 
204).  It is clear that both primary infection and reactivation with KSHV dramatically 
increases the risk of malignant and nonmalignant disease(137, 220, 255, 257, 259, 278).  
However, more studies with larger patient populations need to be done to definitively 
address the clinical significance of primary infection versus reactivation.   
Clearly the most significant risk factor for KS among transplant recipients is 
infection with KSHV.  Though large variation exists in the prevalence of KSHV infection 
based upon geography, a number of serological studies demonstrate that the 
seroprevalence of donors and recipients (prior to transplantation) are similar to each other 
and their general population (Table 1-4)(92, 149, 150, 268, 366).   
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Table 1-4.  Kaposi’s sarcoma associated herpesvirus seroprevalence among transplant donors and recipients 
 
 
Reference 
 
 
Year 
 
Country and 
City/Region 
 
 
Methods 
KSHV 
seropositive pre-
transplant 
 
KSHV seropositive 
post-transplant 
KSHV 
seropositive 
organ donors 
 
 
Population 
        
Rosenzwajg et 
al.(366) 
1999 Paris, France Latent IFA (1:150) 29/200  (14.5%) 36/200(18%)  Bone marrow 
recipients 
Francés et al.(165) 2000 Paris, France 
 
Latent IFA (1:100) 32/400   (8%)   Kidney recipients 
Challine et al.(99) 2001 Paris, France 
 
IFA to latent, (1:40)  15/99  (15.1%) 8/100 (8%) Kidney recipients 
Milliancourt et 
al.(288) 
2001 Paris, France 
 
Latent IFA (1:100) 0/287    (0%) 6/287  (2.1%)  Kidney recipients 
Emond et al.(149) 2002 Paris, France 
 
Latent IFA (1:100) 4/150    (2.7%) 5/150  (3.3%)  Heart recipients 
Marcelin et al.(268) 2004 Paris, France 
 
Latent IFA (1:100) 3/122 (2.4%) 7/122 (5.7%) 4/122 (3.3%) Liver recipients 
Deborska et al.(124) 2002 Warsaw, Poland 
 
IgG ELISA 1/88      (1.1%)   Dialysis patients 
Sheldon et al.(387) 2000 Brussels, Belgium Latent IFA (1:50) 
ORF65/73 ELISA 
15/196  (7.6%) 18/199 (9%) 7/210 (3.3%) Kidney recipients 
Regamey et al.(356) 1998 Basel, 
Switzerland 
ORF65.2 ELISA 
Latent IFA 
14/220  (6.4%) 39/220 (18%)  Kidney recipients 
Enbom et al.(150) 2000 Sweden Lytic IFA (1:40) 
Latent IFA 
8/34      (24%) 
0/34      (0%) 
10/34  (29%) 
0/34    (0%) 
 Bone marrow 
recipients 
Diociaiuti et al.(135) 2000 Rome, Italy 
 
IFA (1:40) 33/66     (50%) 41/66  (62%)  Kidney recipients 
Diociaiuti et al.(135) 2000 Rome, Italy IFA (1:40) 
 
33/120  (27.5%)   Kidney recipients 
Cattani et al.(92) 2001 Rome, Italy 
 
Lytic IFA (1:80) 12/100  (12%) 26/100 (26%)  Kidney recipients 
Andreoni et al.(15) 2001 Rome, Italy Lytic IFA (1:20) 21/130  (16.1%) 34/130 (26%)  97 kidney and 33 
liver recipients 
Delorme et al.(126) 2003 Québec, Canada IgG lytic and latent 
ELISAs 
 0/150  (0%)  Kidney recipients 
Hudnall  et al.(203) 1998 Texas, USA 
 
Lytic IFA (1:40)  29/58 (50%)  Kidney recipients 
Jenkins  et al.(215) 2002 PA, USA Lytic IFA (1:50) 5/95 (5.3%) 15/95 (15.8%)  Solid-organ 
recipients 
Almuneef et al.(9) 2001 Riyadh, Saudi 
Arabia 
Lytic IFA (1:10) 
Immunoblot 
14/201 (7%)   Patients with end-
stage renal disease 
Note: Studies assessed post-transplantation KSHV seropositivity at different times; IFA, immunoflourescence assay. 
Treatment 
Immune reconstitution often leads to remission of KS, therefore reduction or cessation 
of immunosuppressive therapy is often the first line of treatment for patients with a diagnosis 
of transplant-associated KS.  The dual goal for treatment in this population is KS regression 
with maintenance of graft function.  In a study of twelve patients with post-transplant KS, 
Duman et al. reported that reduction or discontinuation of immunosuppressive therapy led to 
complete remission in all patients(143).  In the CTTR, remission was achieved in 33% of non-
visceral KS cases with complete withdrawal of immunosuppressive therapy alone(334, 335, 
337), though the price of remission of post-transplant associated KS was high (Figure 1-3).  
Similarly, Moray et al. found among renal transplant recipients with KS that 4/7 (57%) patients 
with lesions confined to the skin showed complete regression of all lesions after reduction of 
immunosuppression(303). 
Early diagnosis of KS appears critical, as cases with non-visceral involvement can 
often be managed with the reduction of immunosuppressive therapy.  However, patients with 
systemic disease do not respond favorably to adjustments in the therapeutic regimens alone and 
require second-line treatment which can include surgical excision, radiotherapy, cryosurgery, 
and chemotherapy.  Prognosis of patients with systemic KS is often poor and marked with high 
rates of graft loss and mortality. 
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8191 Transplant recipients with a reported malignancy
356 (4.3%) with Kaposi’s sarcoma 
213 (60%) nonvisceral involvement 143 (40%) visceral involvement 151 (42%) with complete remission
113 (53%) with complete remission 38 (27%) with complete remission 7 (5%) had KS recurrence when 
immunosuppression 
 
 
 
36 (32%) had remission with reduction or  
cessation of immunosuppressive therapy alone
23 (61%) had remission with reduction or  
cessation of immunosuppressive therapy alone
  
At least 4 (57%)  lost organ due to graft 
rejection 
 
 
 
 
 
34 kidney recipients with KS remission upon reduction 
or cessation of immunosuppressive therapy 
20 (59%) lost organ  
due to graft rejection 
2 (6%) had impaired function 12 (35%) retained stable function
 
 
 
Figure 1-3.  Cincinnati Transplant Tumor Registry Data 1968-1995
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Though calcineurin inhibitors have increased overall graft and patient survival rates 
compared to treatment with azathioprine and glucocorticoids alone(186), KS is more common 
among patients treated with cyclosporine compared to azathioprine(7, 336).  In a recent case 
report, conversion from cyclosporine treatment to a new immunosuppressive agent, sirolimus, 
led to complete regression of KS lesions among two renal transplant recipients with KS(75).  
Though studies have not yet assessed the risk of KS development on a regimen of sirolimus 
compared to other immunosuppressive therapies, these reports suggest that sirolimus instead of 
calcineurine inhibitors may maintain graft viability while simultaneously protecting against 
initial KS development. 
1.1.2.  Primary Effusion Lymphoma  
 Primary effusion lymphoma (PEL), also known as body cavity based lymphoma 
(BCBL), is a rare subset of AIDS-related non-Hodgkin’s lymphoma, which is a serous effusion 
isolated primarily in the pleura, pericardium or abdominal cavities.  In rare circumstances the 
PEL may present as a solid tumor mass(119).  It is estimated that PELs account for about 3% 
of AIDS-related lymphomas(80).  In 1995, Cesarman et al. demonstrated that KSHV was 
present in all AIDS-related PELs(98), and subsequently others have confirmed these 
findings(79-81, 176, 222, 223, 321, 327).  Of epidemiologic and clinical importance, Cesarman 
reported that approximately 25% of AIDS patients with PEL have KS comorbidity.   
Though KSHV is nearly always identified in patients with PEL, four case reports of 
PEL, among patients with chronic hepatitis C-related (HCV) cirrhosis of the liver, have failed 
to identify KSHV among these patients.  All four patients have been described as KSHV 
negative, HIV negative and EBV negative calling into question whether HCV or other 
unidentified virus may also be responsible for a small subset of PELs(21, 189, 207, 323).  
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Though these four case reports exist, the broader scientific thinking remains that KSHV is 
associated with all forms of PEL. 
 PEL is most common among immunocompromised patients(216, 247, 306), however, 
in rare circumstances, PEL has been observed in otherwise immunocompetent individuals(346, 
409).  The epidemiology of PEL is similar to that of KS, in that age of presentation of disease 
is earlier in HIV-infected individuals (42 years) compared to non-HIV infected individuals (73 
years), and most cases are among HIV infected men who have sex with men, though 
intravenous drug use has been associated with PEL in some European studies(233, 234).  
Overall prognosis of patients with PEL is poor with mortality often observed within 3 months 
of diagnosis(17, 98, 390).  Because of the rarity of PEL, much is still to be elucidated 
regarding causal cofactors among immunocompetent patients.  However, sufficient evidence 
exists to support KSHV as a causal cofactor in the development of PEL, based largely upon the 
strength of association.  
1.1.3.  Multicentric Castleman’s Disease 
 Castleman’s disease was first described 50 years ago by pathologist Dr. Benjamin 
Castleman of Massachusetts General Hospital in a series of case reports(86-88).  Since that 
time, the unique pathological characteristics of the disease have been observed and multiple 
variants of the disease have been described.  One form of Castleman’s disease, a 
lymphoproliferative disorder highly associated with KS, is Multicentric Castleman’s Disease 
(MCD).  The diagnostic criteria for MCD are less well defined than other forms of Castleman’s 
disease with patients often presenting with systemic symptoms including; fever, weight loss, 
splenomegaly, and hepatomegaly.  In addition, patients with MCD have a high rate of KS as a 
comorbidity(84).  Up to 15% of MCD patients may exhibit the rare POEMS syndrome 
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(polyneuropathy, organomegaly, endocrinopathy, multiple myeloma, skin changes)(342).  
Prognosis in patients with MCD is poor with sepsis, multi-organ failure or lymphoma the most 
common causes of death(194, 195). 
Due to the rarity of the disease, the pathoetiology and epidemiology of MCD are not 
fully understood.  As one example, the population prevalence rate of MCD is unknown.  A 
large retrospective study from a cancer center estimated in 1996 the total number of cases in 
the United States to be from 30,000 to 100,000(84).  This may be an underestimate however 
because it is assumed that AIDS-associated MCD is likely under diagnosed(192) due to 
comorbidities which may be preferentially diagnosed among this patient population.   
Early in the discovery of MCD a viral etiology was suspected.  Based upon the 
pathophysiology of the virus EBV was a suspected causal agent.  A number of attempts to 
identify EBV in MCD patients were undertaken and identification of the virus was 
inconsistent(113, 188, 305, 315).  Based upon these results, and because of the higher 
prevalence of EBV in the general population, EBV is thought not to cause MCD. 
MCD can be divided into two separate entities, a plasma cell variant type and a hyaline 
vascular type.  The plasma cell variant is highly associated with KSHV and the hyaline 
vascular type rarely associated with KSHV.  Though EBV is likely not a factor in MCD, 
several lines of evidence exist which demonstrate that KSHV does plays a role in the plasma 
cell variant of MCD.  First, studies of KSHV prevalence among patients with MCD is 
extraordinarily high with prevalence rates among HIV positive individuals reported at 
100%(399, 405).  Among non-HIV infected patients with MCD, only small studies have been 
conducted but the rate of KSHV in these studies has been reported at 0, 41, 81 and 100 
percent(229, 399, 405, 446, 454).  It is assumed that the increase in prevalence among MCD 
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patients with HIV infection compared to the uninfected is explained by the increased rate of 
KSHV naturally observed among HIV infected individuals(432), though this has not been 
proven.  In addition, the low rate of KSHV observed in non-HIV infected individuals is an 
association observed with the hyaline vascular MCD form.  
Additional evidence that KSHV is a factor in MCD is the observation that KSHV DNA 
viral load in PBMCs and plasma increases in association with symptom flare-ups of MCD in 
HIV positive patients.  The counter-trend has been observed as well, where it has been noted 
that  symptoms of MCD regress when KSHV DNA load decreases or becomes undetectable by 
PCR(37, 51, 58, 85, 111, 182, 313).  Lastly, as described by Casper et al., antiviral 
medications, particularly agents used to treat herpesviral infections, have been observed to lead 
to regression of symptoms in HIV-MCD patients(84, 85).   
It is clear that KSHV plays a significant role in the pathogenesis of the plasma cell 
variant of MCD and patients in whom KSHV infection has been established are more likely to 
have poorer outcomes.  The reason for this is likely because the systemic pathologies observed 
in MCD are the result of over expression of the cytokine interleukin 6 (IL-6).  Elevated serum 
levels of IL-6 are a hallmark of MCD.  KSHV expresses a viral analogue of IL-6, viral IL-
6(vIL-6), which shows high sequence homology to human IL-6 (hIL-6)(297), and symptoms 
including pancytopenia, thrombocytopenia and shock can be induced by high levels of vIL-6 in 
MCD patients(432).  The KSHV cytokine vIL-6 contributes to the systemic pathologies 
observed among patients with MCD and some therapies which target KSHV have been shown 
to be effective in treatment.   
Taken together the evidence supports a strong association between KSHV and the 
plasma cell variant of MCD.  This association is thought to be causal, though due to the rarity 
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of the disease, and the fact that most of the current knowledge is based upon case-reports and 
case-series, establishing temporal associations is a difficult task.  The next step in elucidating 
epidemiological questions regarding KSHV and MCD will likely require case-control studies 
with well reasoned controls to obtain a better understanding of the role KSHV plays in the 
natural history and pathogenesis of this disease.  In addition, a shift in nomenclature or a 
concentrated effort to clearly describe MCD as two separate entities (plasma cell versus 
hyaline vascular) would aid in further clarifying the role the virus plays in MCD. 
1.1.4.  Other Disease Associations  
 In a report of three patients, Luppi et al. provide evidence that KSHV infection is likely 
responsible for post-transplant associated bone marrow failure(258).  In a similar report of one 
patient, Cuzzola et al. report a similar finding where KSHV was responsible for bone marrow 
failure after transplantation in a 17 year old girl(121).  Though larger studies are required to 
make firm conclusions and elucidate pathological mechanisms, these case reports are highly 
suggestive that this association is accurate and may be of important public health significance.   
 Apart from the diseases described above (KS, MCD, PEL and perhaps post-transplant 
associated bone marrow failure) there is not sufficient evidence to support a consistent 
exposure-disease association between KSHV and any other clinical condition. However many 
associations have been reported later to be refuted entirely or have yet to be confirmed in a 
robust manner.  Likely the most controversial of these is the reported association between 
multiple myeloma (MM) and KSHV. 
 Shortly after KSHV was first identified, a number of studies were conducted to assess 
viral prevalence among clinical populations with various malignancies and conditions of 
unknown etiologies.  On the whole, these studies were largely null and included studies of MM 
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where the virus was unable to be identified(98, 176, 321, 327).  A subsequent report found that 
KSHV DNA was present in bone marrow dendritic cells of MM patients(360).  Based upon 
these findings a number of groups performed studies of KSHV and MM with varying results.  
Some confirmed the findings that KSHV DNA was present in MM biopsies(6, 32, 66, 67) 
while many others were unable to identify the virus by PCR in bone marrow biopsies or 
peripheral blood(60, 90, 112, 277, 289, 325, 341, 411-413, 420, 448).  As a result multiple 
serological studies were conducted and only one(172), using an immunoblot technique, found 
evidence that KSHV played a role in MM(2, 60, 90, 261, 266, 277, 289, 325, 340, 341, 370, 
436).    
The current evidence appears not to support a KSHV/MM association.  Recently, the 
largest prospective cohort study conducted to date (1,133,000 individuals) was sampled in an 
attempt to be the definitive word on KSHV and MM.  The Joint Nordic prospective study 
group found that KSHV is not associated with MM in a convincing manner(418). 
Isolated case reports of patients with sarcoidosis and KS led investigators to look for 
KSHV DNA among this patient population(116, 128).  A positive association between KSHV 
and sarcoidosis was reported (129, 130) but later refuted by a number of different 
laboratories(34, 166, 169, 232, 244, 262, 406).  In a similar manner KSHV has been associated 
with pemphigus(214, 284, 285, 396), though the strength of this association has been 
questioned(40, 91, 107, 145).  A number of other associations, including primary and 
secondary pulmonary hypertension have been found but ultimately refuted (see chapter 3).  For 
a more comprehensive discussion of the diseases in which KSHV does not appear to be 
associated, Cohen et al. have recently put together a compendium of the populations in which 
studies have been conducted on KSHV prevalence (reviewed in (106)). 
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1.2.  Etiology of Kaposi’s Sarcoma 
 Substantial evidence exists to support the argument that KSHV is the etiologic agent of 
KS, though in most individuals infection alone will not lead to disease.  In AIDS and 
transplant-associated KS, underlying immunosuppression appears to be an important and 
necessary cofactor.  Though perhaps not sufficient, KSHV is necessary for KS.  The following 
sections are designed to demonstrate in a systematic way that KSHV is the causative agent of 
KS.  Using Sir Austin Bradford Hill’s criteria for causality as a model, the causal association of 
KSHV with KS is explored. 
Bradford-Hill Criteria for Causality 
 In an attempt to demonstrate the difficulty in characterizing the differences between 
simple associations and causal associations, Hill described in 1965 a set of criteria which could 
aid scientists and epidemiologists in systematically compiling evidence to determine if among 
an observed or hypothesized exposure-disease relationship the exposure of interest actually 
causes the disease(61, 196).  Hill’s original criteria include strength of association, consistency, 
specificity, temporality, biological gradient, biological plausibility, coherence, experimental 
evidence and analogy.  He notes that some of the criteria are of more importance than others in 
determining causality and not all criteria can or need to be demonstrated to establish evidence 
for a causal association.  However, as an exercise in assessing whether KSHV is the causative 
agent of KS the criteria are used as a model to evaluate this exposure-disease relationship. 
1.2.1.  Strength of Association 
 The first criterion Hill describes is strength of association.  Specifically in this setting, 
we must address the following: is the prevalence of KSHV among patients with KS great 
enough to reasonably support an actual and important association? If an observed association is 
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particularly strong it provides evidence that the observation is less likely to be comprised 
entirely of confounding factors or information bias.  In early investigations of smoking and 
lung cancer it was observed that among individuals who smoke, mortality from lung cancer 
was about 10 times greater than among non-smokers.  Based upon this information alone, 
many believed that smoking was likely the cause of the excess cases of lung cancer.  As a 
comparison, for KSHV, the odds of detecting the virus in KS lesions compared to a normal 
tissue site exceed 100(317, 373).  
 KSHV DNA is routinely detected in greater than 95% of all KS lesions by PCR 
techniques.  In studies using unaffected skin areas from the same patients with KS, the chance 
of detecting KSHV DNA is greatly reduced.  Additionally, among control tissues obtained 
from patients with no clinical signs of KS, KSHV DNA is rarely amplified in PCR 
reactions(10, 69, 114, 144, 170, 246, 269, 298).  These studies are highly suggestive that KS 
lesions harbor KSHV at a rate much higher than control tissues. 
In addition to tissue studies, which can identify viral DNA at the site of KS lesions, 
serological evidence supports an association between KSHV and KS.  Antibodies to KSHV are 
more common among patients with KS compared to patients without KS.  Additionally among 
patients known to be infected with KSHV, antibody titers are higher among patients with KS 
compared to non-KS groups(41, 76, 103, 241, 392).  Seroepidemiology studies have 
characterized worldwide seroprevalence rates of KSHV.  KS disease rates in endemic regions 
roughly follow the same geographical pattern.  Though using trend data and ecological 
associations are not criteria in which to base definitive “proof” of causality, the strength and 
consistency of these observations are difficult to dismiss outright.     
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Overall the strength of association between KSHV and KS is strong with ample 
evidence to suggest that KSHV is consistently present in KS tumors and antibodies to KSHV 
are common among patients with KS, though the virus is not ubiquitous in the general 
population.     
1.2.2.  Consistency    
 Hill defines this criterion the following way; has the observed association been 
repeatedly observed in different places, circumstances and times?  For the KSHV-KS disease 
exposure association the evidence is overwhelming that indeed the consistency criterion is 
fulfilled.   In studies using tissue from KS lesions, different laboratories using different 
techniques are highly consistent in their ability to detect KSHV in all forms of KS.  In the past, 
variation did exist in detection rates based upon PCR detection methods and the quality and 
type of tissue examined. For example, it has been noted that DNA detection rates are higher 
among fresh lesions compared to stored paraffin embedded tissues(100, 101, 298, 300).  
Though these problems have been noted, multiple studies conducted in more recent years show 
a high rate of concordance in the ability to detect KSHV DNA in KS lesions.  Scientific 
consensus has been reached with respect to the consistency of these findings. 
1.2.3.  Specificity 
 On specificity, Hill states “If specificity exists we may be able to draw conclusions 
without hesitation; if it is not apparent, we are not thereby necessarily left sitting on the fence.”  
In general, when discussing viral etiologies, strict specificity is not a criterion in which one is 
able to draw such causal conclusions without hesitation.  Because KSHV is clearly associated 
with pathologies other than KS (as discussed in section 1.1.), adherence to the specificity 
criterion in the classical sense would appear not to be met.  However a number of viruses, 
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including other herpesviruses, are known to produce multiple syndromes, diseases and 
disorders.  Specificity of association may be useful in assessing causality of environmental 
exposures, though in assessing the pathoetiologies of potential tumor viruses it may not be as 
important a criterion.   
In a sentinel work addressing this issue, Moore and Chang in the American Journal of 
Epidemiology, lay out a new way of thinking with respect to specificity of effect using as an 
example the closely related Epstein-Barr virus (EBV)(299).  Because specificity of effect could 
not be demonstrated for the EBV-Burkitt’s lymphoma association, some factions continued to 
argue that EBV was not causal for the disease even when faced with molecular proof.  Moore 
and Chang argue that though Hill’s criteria are of great utility, molecular techniques which 
have the ability to often elucidate causal associations alone should not continue to be left 
ignored by those who are disciples of the 1965 criteria.   
It is not that KSHV infection is not specific to KS.  To the contrary, as described in the 
previous “strength of association” section, KSHV DNA is localized to the site of KS lesions.  
However, KSHV is not uniquely specific to KS, as PEL and MCD are also clearly caused by 
the virus.  In regard to the KSHV-KS interaction we cannot “draw conclusions without 
hesitation” with the specificity of effect criterion.  However, it is likely that few tumor causing 
viruses show this type of specificity. 
1.2.4.  Temporality 
 For an exposure to be truly causal the correct temporal relationship between exposure 
and disease must be established.  KSHV must precede and predict the development of KS to be 
considered the etiologic agent.  The type of study design required for assessing the proper 
sequence requires a cohort of individuals who are initially disease free and exposure free.  The 
28
 
cohort then needs to be followed over time to assess the actual sequence of events.  
Specifically, does exposure (KSHV infection) always precede disease (KS)?  The 1996 AIDS 
paper “KSHV infection prior to onset of KS” seemed to provide sufficient evidence that the 
correct temporal trend was observed(302).  This study tested serial PBMC samples from HIV 
infected individuals prior to and after the development of KS.  Patients who developed KS 
were at substantially greater risk of KSHV infection prior to development of disease compared 
to patients who did not develop KS.  In another population of HIV infected individuals, 
patients who had detectable levels of KSHV DNA present at enrollment were at substantially 
greater risk of developing KS compared to the participants who were not PCR positive(438).  
Since those early studies, additional evidence has emerged in numerous studies of different 
designs and methods that confirm these findings (Table 1-5).   
 
Table 1-5.  Temporal association of KSHV and KS: evidence which supports the condition 
that exposure precedes disease 
 
Evidence 
 
Selected Reference List 
 
DNA detection and proliferation prior to KS in HIV cohorts 
 
Moore et al. 1996(302) 
Whitby et al. 1995(437) 
 
 
KSHV seroconversion prior to KS in HIV cohorts 
 
Gao et al. 1996(173) 
Melbye et al. 1998 (283) 
Renwick et al. 1998(359) 
 
 
Serological detection of KSHV prior to organ transplantation 
and KS 
 
Andreoni et al. 2001(15) 
Jenkins et al.2002(215) 
Luppi et al. 2000(256) 
Parravicini et al. 1997(326) 
 
 
Primary infection after transplantation leads to KS 
Collart et al. 2004(108) 
Luppi et al. 2000(257) 
Luppi et al.2003(254) 
Regamey et al. 1998(356) 
 
Note:  References presented reflect a selection of important works and are not a complete list of all 
studies performed on KSHV/KS temporality. 
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More recent studies done in the transplant setting have elegantly shown the temporality 
of the KSHV-KS relationship.  Patients negative for KSHV can be infected through solid organ 
transplantation and subsequently develop KS(30, 296).  Marcelin et al. showed that among 
liver transplant recipients, 100% of KSHV negative recipients who received a KSHV-infected 
allograft seroconverted within 6 months post-transplantation.  Of those, 50% developed 
Kaposi’s sarcoma and died of multiorgan failure within 1 year post-transplantation (268).  This 
study nicely demonstrated the temporality of infection and disease.  Evidence has shown that 
in all cases in which the temporal association between KSHV and KS has been assessed that 
KSHV precedes KS.  The Hill criterion of temporality appears to be met in the present setting. 
1.2.5.   Biological Gradient 
 Traditionally the biological gradient criterion has been thought of in terms of a dose-
response relationship.  As an example, the risk of lung cancer is not simply a dichotomous 
association.  It has been shown that as the number of cigarettes consumed increases so too does 
the associated risk of disease.  In terms of dose response the question would be; is more 
exposure to KSHV associated with KS?  To know for certain the amount of exposure to KSHV 
an individual encounters is not possible.  However, in one study, KSHV superinfection, as 
evidenced by identification of multiple strains of KSHV in the same individual, has been 
shown among patients with and without KS(39).  In most viral diseases superinfection is a risk 
factor for disease development, though in the setting of KSHV the actual significance of 
superinfection is currently unknown.  For most viral infections, defining dose response in this 
manner may not provide the most utility in attempting to understandexposure-disease 
associations.   
30
 
 In a similar consideration of KSHV using the Hill criteria, Sarid et al. define the 
biologic gradient criterion in terms of the location of KSHV DNA within individuals with KS.  
Most studies have demonstrated that detection rates and KSHV DNA viral load is greater in 
biopsies taken directly from a KS lesion compared to unaffected tissue sampled from the same 
patient(10, 55, 100, 144, 243, 246, 269, 298, 311).  Exceptions exist among KS patients with 
advanced KS and disseminated infection(69, 114).  However, based on this definition of the 
biologic gradient, KSHV DNA is present more frequently in KS lesions compared to 
unaffected tissues and therefore fulfills the criterion. 
1.2.6.  Biological Plausibility 
As with all members of family Herpesviridae characterized to date, KSHV is a large 
virus and has a linear double stranded DNA conformation.  A member of the 
gammaherpesvirus subfamily, KSHV is most closely related to herpesvirus saimiri of squirrel 
monkeys and Epstein-Barr virus (EBV) of humans(295).  Figure 1-4 represents the phylogentic 
relationship among KSHV and other herpesviruses.  Gammaherpesviruses are known to infect 
lymphocytes and cause tumors in both animals and humans.  For example, EBV is known to 
cause Burkitt’s lymphoma and nasopharyngeal carcinoma(322, 419, 449).  Because related 
viruses have been shown to be oncogenic it is certainly plausible that KSHV causes KS. 
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 Figure 1-4. Phylogenetic tree of KSHV and other herpesviruses.  Figure from Moore 1996 et al. J. 
Virol70:549-58.(301) 
 
In Hill’s original description of the criterion, he minimizes the importance of 
plausibility.  He argues that biologic plausibility is dependent upon the biological knowledge 
of the day.  Therefore, a concept which is seemingly implausible may at some point become 
plausible given novel scientific findings uncover mechanisms which up to that time had gone 
unobserved.  This is precisely what has happened in the setting of KSHV and KS.  In the 
1980’s, for many, the thought that KS was caused by an infection other than HIV was entirely 
implausible.  For a minority, (35) it seemed patently clear that KS was caused by an infectious 
agent distinct from HIV.  Based upon new scientific findings(100, 298), namely the 
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identification of KSHV and research establishing that KSHV encodes multiple viral 
oncogenes, mass opinion shifted and now most scientist agree that not only is it biologically 
plausible but scientifically proven that KSHV is the etiologic agent of KS. 
1.2.7.  Coherence 
 Coherence is not unlike biological plausibility but interpretation is made using only the 
biological understanding that is currently known of the exposure and disease relationship.  The 
cause and effect interpretation of the available data should not seriously conflict with the 
generally known facts of the natural history and biology of KS.  When Beral et al. proposed 
that KS may have an infectious disease etiology certain assumptions were made that proved 
later to be correct.  For example, KSHV is not a ubiquitous infection but rather has a 
worldwide prevalence that is quite low.  KSHV is largely asymptomatic among those infected 
but among groups at high risk for KS, especially among individuals who are 
immunocompromised, KS can be quite aggressive.  Infection with KSHV appears to be highly 
associated within individuals already at high risk for KS, especially among men with 
AIDS(227, 265, 275, 287, 326, 397).  In addition, the geographic distribution of KSHV 
infection (Figure 1-7) appears to be highly associated with the global prevalence of KS disease.  
In conclusion, there appears to be no serious conflict or contraindication, with what is known 
about the biology and natural history of KS, in the assumption that KSHV causes KS.   
1.2.8.  Experimental Evidence 
 Though perhaps the most convincing way to demonstrate causality is through direct 
scientific experimentation, in the setting of KSHV and KS, human experimentation is clearly 
unethical.  Therefore a strict interpretation of the criterion would yield it unfulfilled.  However, 
indirect experimental evidence through clinical trials can provide useful information when 
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attempting to establish causality.  Multiple studies establishing the efficacy of the anti-herpes 
drugs ganciclovir and foscarnet have demonstrated that these agents prevent the onset of 
KS(117, 178, 217, 242, 272, 291, 351, 364).  In one clinical trial where patients were randomly 
assigned treatments, Martin et al. show that a course of oral ganciclovir reduced the risk of 
developing KS by 75%.  More dramatically they showed that intravenous treatment reduced 
the incidence by 95%(272).  These results are highly suggestive that treatments with agents 
used to target herpes infections are protective against KS onset.  Though this is not direct 
evidence the strength of these observations bolsters the argument that KSHV causes KS. 
1.2.9  Discussion of KS and Causality Criteria 
 In creating these criteria for causality, Hill makes clear that it is not possible to lay 
down hard and fast rules by which causality can be definitively assessed.  However these nine 
principles do provide a framework in which we can begin to make informed decisions 
regarding causal associations.  In assessing whether KSHV is the etiologic agent of KS the 
weight of evidence using the Hill criteria is strongly in favor of the hypothesis.  Factors in 
addition to KSHV, namely immunosuppression, may also be required for disease however 
KSHV appears to be a necessary condition in all forms of KS.   
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1.3. Methods for Detecting KSHV infection 
A number of techniques have been employed for defining infection in individuals and 
include both molecular and serological methods.  KSHV has been identified in cells, tissues, 
and body fluids through exploiting these different approaches individually and in combined 
formats. 
1.3.1. Detection of KSHV by Polymerase Chain Reaction (PCR) 
 
PCR methods are most often used for the detection of KSHV DNA.  Initial studies have 
demonstrated that at least 95% of KS lesions harbor KSHV DNA that can be amplified by 
PCR(98, 100, 200, 211, 373, 378, 379).  However, detection of KSHV DNA load in peripheral 
blood samples from patients with KS is substantially lower and is often not detected, though 
nested PCR has been shown to increase the ability to detect DNA (76, 302, 391, 400, 438).  
PCR detection during latent infection among patients without active KS is likely low and 
therefore the utility of PCR as a tool for definitive diagnosis in the general population is 
limited.  In addition, PCR contamination has been observed as a potential problem in testing 
samples for KSHV(227, 434) and has led to a number of disease associations(36, 129, 352, 
360) which were later proved to be false due to contamination(2, 97, 172, 244, 341, 354).  
Because of these disadvantages and controversies, PCR has proven not to be a reliable method 
for large scale population screening studies of KSHV. 
1.3.2.  Detection of KSHV by Immunohistochemistry (IHC) 
 
KSHV can be detected in paraffin-embedded human tissue using IHC and is used as a 
technique for pathological confirmation of KS.  A variety of antibodies to KSHV antigens are 
available for IHC, though the reliability of some of these commercially available antibodies 
has been questioned.  This technique has proven useful for detecting KSHV among patients 
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with Castleman’s disease, among tumors from patients with primary effusion lymphoma (PEL) 
and from lesions derived from KS patients.   Because tissue is required and antibody reactivity 
varies this technique is considered useful only for pathological diagnosis and is not generally 
available for screening studies.  Some studies have used IHC to determine KSHV prevalence 
in tissues taken at autopsy from patients with no serological evidence of KSHV infection(110).  
In a previous report we have pointed out that IHC may be prone to misdiagnosis of uninfected 
individuals due to the inherent subjectivity of the method and also the potential for nonspecific 
binding of antibodies(240).  
1.3.3.  Detection of KSHV by Serology  
 
It is likely that the most efficient and accurate method for diagnosis of KSHV infection 
is through serological techniques.  Katano and colleagues identified a number of antigens that 
are useful for examining KSHV in sera from KS patients.  These antigens are encoded by open 
reading frames (ORF) 6, 8, 9 25, 26, 39, 59, 65, 68, 73, K8.1A and K8.1B(226).  Various 
serological methods have been developed for KSHV detection.  Immunofluorescence assays 
which target both latent and lytic antibodies, immunoblot assays, and enzyme-linked 
immunosorbent assays, which have primarily been used to target lytic antibodies, have all been 
used with varying levels of sensitivity and specificity.    
Serological detection of KSHV by Western blot 
 
 Western blotting for KSHV has been performed targeting a variety of viral 
proteins(173, 287, 349, 353, 391).  Gao et al. first showed that sera from patients with KS were 
reactive to the latent protein encoded by ORF73 (LANA) by Western blot with 80% 
sensitivity.  Figure 1-5 is an example of a typical Western blot.  This protein, which is 
localized to the nucleus has been the primary latent antigen used in the serological assays of 
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other formats which followed.  Though LANA and other viral antigens have been run on 
Western blots, for serological testing, this method has been largely replaced by IFA and ELISA 
assays due to the technical aspects associated with this technique and the relatively low 
specificity of the assay.   
 
 
Figure 1-5. 
Representative Immunoblots of Serum Samples from a Patient with AIDS-Associated Kaposi’s 
Sarcoma (Panel A) and a Patient with AIDS but No Kaposi’s Sarcoma (Panel B).   Reproduced 
from Gao et al. 1996  N Engl J Med. 335:233-241.(173)  
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Serological detection of KSHV by Immunofluorescence Assays (IFA) 
 
 One of the first serological tests developed for detection of KSHV in sera was the 
indirect IFA which targets LANA.  An example of an IFA from an AIDS-KS patient is 
presented in figure 1-6.  LANA is composed primarily of the gene product ORF73 and is 
responsible for the episomal maintenance of HHV-8 genomes in latently infected cells.  The 
three most commonly used cell lines used to prepare the test are BC-1, BCP-1 and BCBL-
1(174, 249, 287, 301, 357) and are all chronically infected with KSHV and continuously 
express latent antigens.  The BC-1 cell line is coinfected with Epstein-Barr virus (EBV), a 
herpesvirus related to KSHV, and cross-reactivity between the viruses has been observed(13, 
287, 399).  The BCBL-1 cell line is EBV negative which has allowed for the creation of more 
sensitive IFAs for the detection of KSHV(357). 
Sera From Patient With KS
Human Sera Anti-LANA1
DAPI Merge
 
Figure 1-6. Immunoflourescence assay staining for an individual infected with KSHV 
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One method, which has been used for increasing whole cell IFA sensitivity, is 
induction of lytic antibody production in the cells through treatment with phorbol esters (TPA 
treatment) or butyrate(71, 103, 249, 397).  This method allows for detection of structural (lytic) 
proteins through immunofluorescence.  However, evidence suggests that due to the homology 
of structural proteins across herpesviruses this may be a mechanism for cross-reactivity.  For 
example, Moore et al. demonstrated that some structural proteins of KSHV show high 
homology, up to 50%, with EBV(301).  Therefore patients identified as KSHV positive by this 
method may instead be infected with the more common EBV virus.   
In one study of US blood donors, the KSHV seroprevalence rates were significantly 
higher using the lytic IFA compared to other serological techniques(333).  In published studies 
where assay performance was directly compared between the two methods, the lytic IFA 
consistently produced more positive results compared to the latent IFA (Table 1-6).   
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Table 1-6.   Direct comparison of KSHV seroprevalence using lytic and   
latent IFAs as previously reported 
 
Population 
 
Prevalence 
Lytic IFA 
 
Prevalence 
Latent IFA 
 
Percent 
Difference 
 
Reference 
 
Outpatient hospital attendees – 
Cameroon 
 
 
 
50.5 
 
 
25.3 
 
 
50.0% 
Pregnant women – Uganda 
 
44.8 27.0 39.7% 
Children – Egypt 
 
42.4 6.4 84.9% 
Italian blood donors 18.7 12.7 32.1% 
 
 
 
Serraino et al. 
(2002)(384) 
     
KS patients 
 
88.0 88.0 0.0% 
Swedish blood donors 
 
20.0 0.6 97.0% 
Individuals with high risk 
sexual behavior 
 
 
30.0 
 
3.5 
 
88.3% 
Bone marrow transplant 
recipients – pre-transplant 
 
 
24.0 
 
0.0 
 
100% 
Bone marrow transplant 
recipients – post-transplant 
 
29.0 
 
0.0 
 
100% 
 
 
 
 
Enbom et al. 
(2000)(150) 
     
US blood donors 23.0 5.0 78.3% Hudnall et al. 
(2003)(202) 
     
KS patients 
 
93.0 85.0 8.6% 
Italian blood donors 22.0 2.6 88.2% 
Tedeschi et al. 
(2000)(416) 
     
KS patients 
 
83.3 66.6 20.0% 
STD patients 
 
48.8 13.7 71.9% 
Italian blood donors 
 
27.7 2.1 92.4% 
 
Rezza et al. 
(1998)(362) 
 
In addition, assay comparison studies show a high rate of discordance between the lytic 
IFA compared to other serological techniques; techniques that have a high degree of inter-
assay agreement.  This supports the argument that though sensitive, the lytic IFA is likely of 
little value in regard to specificity.  An additional problem, which has been noted with the IFA, 
is the occurrence of nonspecific reactivity among sera with high lipid content and among 
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certain patient populations.  Populations which have been shown to produce this nonspecific 
reactivity include sera from individuals with a high number of sexual partners, patients with 
parasitic infections and among people exposed to a high number of pathogens(102).  In 
addition, patients with autoimmune disease or other hematological perturbations may be more 
likely to cause false-positive KSHV test results (chapter 2). 
Overall the IFA assays have provided initial estimates of KSHV infection rates in 
various populations, have provided evidence that KSHV is the causative agent of KS and are 
easier and more quickly performed compared to immunoblotting.  However, as an independent 
diagnostic tool, the latent IFAs lack a certain degree of sensitivity (~80%) and the lytic IFAs 
lack specificity (<80%). 
Serological detection of KSHV by Enzyme-Linked Immunosorbent Assays (ELISA) 
 
As with the other serological techniques for defining KSHV infection, ELISA systems 
are used only in laboratory research to diagnose infection because no single ELISA assay has 
demonstrated consistent sensitivity and specificity high enough to be of clinical utility.  A few 
ELISA formats are available commercially; however, the majorities exist as home-made 
preparations.  This has made interpretation of seroepidemiology studies difficult because the 
techniques are often unique to an individual laboratory and specific and complete 
methodologies are often left unexplained.  In addition, as with the IFA assays, performance of 
the ELISA assays appears to be highly dependent upon the study population being tested(3, 
102, 372). 
Various antigen preparations have been used for the ELISA serological methods and 
include the use of whole viral lysates, recombinant peptides and synthetic peptide preparations.  
Most KSHV ELISA assays are based upon detection of lytic antibody to KSHV.  Many use 
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specific antigens, such as ORF65, which has been developed to target antibodies to the KSHV 
major capsid protein(329, 350, 391).  One of the other more commonly used lytic ELISA 
assays is based on ORF K8.1 (238) which has been consistently shown to have higher 
sensitivity and specificity than many of the other serological techniques.  This is likely due to 
the fact that K8.1 is highly immunogenic and has no homolog in other herpesviruses(208, 209, 
238, 252, 400).   
ELISA assays which target lytic viral antigens have been found to be of highest 
sensitivity and overall accuracy in assay comparison studies, though concordance between 
these assays has varied.  Rabkin et al. performed an assay comparison study which found 
considerable variation between the assays(350).  In a similar study, Enbom et al. noted similar 
inconsistencies in sensitivity and specificity with questionable consistency between different 
methods(150).   
Using second-generation KSHV serological assays, Schatz et al. found higher 
concordance rates(375).  However, though different laboratories participated in the study, the 
assays used in the study largely targeted the same viral antigens.  No latent class analysis or 
other type of weighting was performed to account for the correlation between assays.  
Therefore the higher inter-assay concordance reported may be in part to inherently low within-
assay variation as opposed to concordance between completely different serological assays.  If 
this is indeed the case, it does provide evidence that the overall reproducibility of the methods 
are high (between-laboratory variation using similar methods is low). 
A comparative assay study conducted more recently among US blood donors by Pellett 
et al. took into account within-assay similarities.  Using a latent-class analysis they determined 
the rate of KSHV infection among US blood donors to be 3.3%(333).  The laboratories which 
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participated in the study used multiple assays to define KSHV seroprevalence and the outcome 
measure of this study was a laboratory’s definition of KSHV positivity; therefore, individual 
assay performance was not directly reported.  However, of the 40 blinded positive controls 
(from highly seroreactive KS patients) all laboratories identified the specimens accurately as 
KSHV positive.  Among the 1000 blood donors that were tested the range of seropositivity was 
0.5% (5/1000) to 3.7% (37/1000).  All of the laboratories found low rates of KSHV positivity 
in the group of blood donors, however, the kappa values reported were very low.  This 
suggests that if the same study was conducted in a population where the KSHV seroprevalence 
rate was higher (nearer 50%) assay discordance would be very high and laboratory agreement 
would be low. 
Attempts to design an ELISA assay which targets LANA have been reported with 
varying levels of success.  Initially, Olsen et al. mapped ORF73 (LANA1) for peptides which 
could potentially be used in an ELISA format(318).  Though 13 potential peptides were 
identified, individually, sensitivities of the products were low (11%-44%).  In a combined 
format the sensitivity of the assay was increased to 78%.  Using the Semliki Forest virus 
system, Corchero et al. produced KSHV LANA for use in an ELISA format(115).  They report 
however that lytic antigens are universally more useful than latent antigen-based ELISAs in 
detecting KSHV infection.  The methods described by these two groups have not been adopted 
by others for common use.   
Researchers at the National Cancer Institute (NCI) report of a full-length baculovirus-
expressed LANA/ORF73 protein with 99% specificity and 84% sensitivity, though these data 
have failed to be published.  Reproducibility of these numbers has been questionable because 
among the published seroepidemiology studies which report the use of this assay system, none 
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adequately describes the methods for performing the assay(153, 280, 441), and the overall 
utility of the assay has been brought into question by the group which has used it in the past. 
There is currently no intention to continue use of this serologic method in future 
seroepidemiology studies conducted at NCI due to problems with consistency (Personal 
communication, Denise Whitby). 
As described in detail in chapter 2, we describe a novel recombinant LANA1-gst 
ELISA which provides a high degree of sensitivity and specificity when used in a combined 
format with the ORF65 and K8.1 lytic ELISA systems.  In addition, further discussion of 
ELISA serological techniques for defining KSHV infection and the associated complications 
that have been observed are explored in the article. 
1.4 The Epidemiology and Seroepidemiology of KSHV 
In the following section, the epidemiology of KSHV is reviewed including transmission 
modalities, clinical course in various populations and treatment options for individuals 
infected.  In addition, the chapter explores in depth the seroepidemiology of KSHV including, 
a summary of global KSHV infection rates, as defined by serological methods, and a 
discussion of the adequacy of the assays currently available for serological definition of KSHV 
infection.   
1.4.1. KSHV Transmission 
 Though considerable efforts have been made to explain the routes of KSHV infection, 
the precise mode(s) of transmission have yet to be adequately elucidated.  A number of 
potential routes of transmission are possible because KSHV has been isolated in a number of 
tissues and body fluids from infected individuals including blood, semen and prostate 
tissues(114, 199, 292, 332), the genital tract of women(442), uncommonly in rectal samples 
44
 
(76) and urine(371) and most commonly in saliva and oral fluids(235, 330, 426). 
Epidemiologically, sufficient evidence exists to support both sexual and nonsexual 
transmission modalities. 
1.4.1.1 Sexual Transmission of KSHV 
 KSHV can be transmitted through sexual contact and in North America and Europe is 
likely the most important transmission pathway.  Studies have shown that male homosexual 
transmission is the primary route; however, heterosexual transmission has been reported.  
Homosexual Transmission 
A number of studies demonstrate that among homosexual men KSHV transmission 
occurs via a sexual route(131, 141, 227, 275, 283, 310, 355), though the precise mechanism of 
transmission has not been fully established.  Correlations have been demonstrated between 
specific sexual practices and increased KSHV seropositivity and include receptive anal 
intercourse, insertive anilingus, total number of sex partners, and deep kissing with an HIV 
infected partner(184, 275, 283, 310, 330).  In addition, saliva as a lubricant for penetrative sex 
may be an important transmission route(78).  Though these correlations have been noted, few 
studies have prospectively assessed sexual practices and KSHV seroconversion, making 
temporal conclusions with the current data not possible.  Further confounding these 
associations is that multiple specific individual sexual practices are commonly practiced by 
individuals, making isolated inferences regarding a unique sexual transmission mode difficult 
to study.  One study does report that orogenital receptive and insertive sex with more than 5 
partners in 6 months was an independent risk factor for seroconversion(141).  It is currently 
unclear whether the risk of KSHV infection is elevated or diminished among homosexual 
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women.  Studies of homosexual female risk factors are required for an understanding of 
potential transmission pathways among this population. 
Heterosexual Transmission 
Definitive proof for heterosexual transmission is still lacking largely due to conflicting 
studies using different KSHV detection methods.  However, the weight of evidence suggests 
that heterosexual transmission of KSHV is likely, though KSHV transmission efficiency via 
penile-vaginal sex is low. Studies of female commercial sex workers have shown that KSHV 
seroprevalence is higher among women with at least one other sexually transmitted disease, 
suggesting a sexual transmission route(148, 267).  In one African study of rural families, 
women married to a KSHV positive man had a sevenfold risk of infection providing further 
evidence that KSHV is likely transmitted sexually between spouses(281).  To date, studies 
show evidence of unidirectional male to female infection via a heterosexual route but currently 
evidence is lacking for conclusions to be made regarding female to male transmission through 
a sexual route. 
1.4.1.2.  Nonsexual Transmission of KSHV 
 Several studies suggest transmission via nonsexual contact is common in KSHV 
endemic areas such as Africa and the Mediterranean.  Various lines of evidence support 
nonsexual transmission.  For example, in endemic areas seroprevalence is elevated among 
children and increases with age to near adult levels prior to adolescence(14, 78, 177, 260, 279, 
281, 316, 344, 383) and KSHV clustering within families and crowding have been observed as 
important risk factors for nonsexual transmission(16, 123, 344, 440).  In addition, recent 
reports have demonstrated that infection through infected blood products and transplanted 
organs is possible. 
46
 
KSHV transmission via close nonsexual contact 
Mother-to-child transmission studies have been undertaken and can be loosely placed 
into three categories based upon their findings:  (1) horizontal mother-to-child transmission 
occurs (59, 65, 190, 224, 260, 344, 377) and is associated with increasing maternal antibody 
titer level(125, 344, 394). (2) vertical mother-to-child transmission is unlikely or extremely 
rare(142), and (3) KSHV infected mothers can passively transmit antibodies to their infants 
who later serorevert(72, 78, 89, 177, 260).   
 In utero transmission has not been sufficiently demonstrated(180).  However, some 
studies have found KSHV DNA present among newborn infants using PCR techniques, though 
infrequently(65, 263, 264).    Transmission through breast milk is unlikely(64) though KSHV 
DNA was isolated in one study(125).  Antibodies to KSHV have been isolated in breast milk 
but it is believed that these are passively transmitted and the probability that infectious virus is 
transmitted through this mechanism is at most very uncommon and would likely require an 
aggessive dissimenated maternal infection with KSHV. 
 The mechanism by which nonsexual transmission occurs is not known with certainty.  
However, oral shedding of KSHV is the leading hypothesis and has been demonstrated as a 
mode of transmission(427).  KSHV DNA copy number in saliva is higher than in other body 
fluids (48, 330).  Taken together, the weight of evidence suggests KSHV is transmitted 
nonsexually in endemic populations likely through salivary contact.  By whichever mechanism 
transmission occurs, horizontal transmission is the primary route of non-sexual KSHV 
infection with vertical transmission unlikely to occur, although definitive evidence is still 
lacking. 
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KSHV transmission via blood 
 Transmission through blood and blood products has been demonstrated though 
transmission efficiency via this route appears to be low.  In the past, transmission of KSHV 
through blood products has been discounted due to the low rates of KS observed among 
hemophilics and IV drug users.  However, increasing intravenous drug use was found to be 
associated with an increase in KSHV seroprevalence among a large cohort of women in the 
United States(77) and has also been found to be an independent risk factor for KSHV infection 
among men and women in international studies(38, 358, 359, 362, 398).  These findings 
suggest needle-sharing and inter-person blood transfer is a possible mechanism for KSHV 
transmission. 
 Studies of KSHV among blood donors have shown that KSHV infected individuals do 
provide blood products for transfusion to others (28, 33, 47, 73, 99, 103, 123, 150, 152, 163, 
171, 198, 202, 219, 236).  Early on, some argued that transmission via this route was 
biologically plausible (152), though early studies based on small samples did not find evidence 
of transfusion-associated transmission(154, 319).  The risk of becoming infected through 
infected blood products is not clear, however larger and more recent studies conducted in 
Africa estimate KSHV transmission risk to be around 3% per transfusion(154, 280).   
A recent study conducted in the US demonstrates that transfusion-associated 
transmission is likely to occur and estimates the KSHV transmission risk per transfused 
component to be less than 0.1%(136).  Though the effective transmission rate of infection is 
low, the number of transfusions per year is high.  The American Association of Blood Banks 
estimates that approximately 5 million transfusions occur in the US each year(11).  Based upon 
these estimates, up to 5,000 cases of transfusion-associated KSHV infections can be expected 
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to occur every year in the United States.  Taken together the body of evidence supports blood 
transmission as a possible route of KSHV transmission but with low efficiency. 
KSHV transmission via organ transplantation 
Solid organ transplant recipients can acquire KSHV from infected donor organs(30, 
256, 268, 288, 308, 326, 356).  Though the exact viral transmission efficiency via this route is 
unknown, the probability of seronegative transplant recipients becoming infected with KSHV 
through infected renal allografts has been estimated to be 2%-12%(288, 356).    One report of 
28 cases of posttransplantation KS showed that 82% of KS cases were due to KSHV 
reactivation and 18% were due to new infection from the transplanted organ(256).  
Additionally, recipients who become infected through one of the traditional transmission 
pathways post-transplantation are at increased risk for developing KS.  It is currently unclear 
whether KS risk differs between recipients with denovo infection from an infected organ 
compared to those with viral reactivation or post-transplant primary infection. 
1.5. KSHV Seroepidemiology 
Largely as a result of seroepidemiology studies, much has been determined regarding 
the basic epidemiology of KSHV including modes of transmission, disease associations and 
pathological consequences of infection, including risks factors for developing KS.  
Additionally, seroepidemiology studies of KSHV have categorized the global distribution of 
KSHV infection and have provided an understanding of clinical and behavioral risk factors that 
are associated with infection.   
 Though no gold standard assays exist for KSHV, certain trends are clear.  For example, 
seroepidemiology studies have shown that KSHV is not a ubiquitous virus worldwide, as are 
most other herpesviruses.  In addition, studies of KSHV prevalence suggest that KSHV 
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infection is persistent, as is EBV and HHV-6, as demonstrated through the correlation of 
prevalence with age(316).  Current serological techniques have uncovered these phenomena 
and the sensitivity and specificity of these assays has not been a problem in elucidating these 
associations among some high risk populations.  However, the utility of these assays in low-
titer, low-risk populations is unclear.  The largest discrepancies between KSHV assays and 
laboratory interpretation of assay results arise in the populations at lowest risk of developing 
KS.  For example, a number of reports suggest the KSHV seroprevalence among the US blood 
donor population is likely less than 5%(333).  However, others have postulated that a large 
proportion of the general population classified as uninfected by many serological assays and 
PCR techniques are actually asymptomatically KSHV infected in low risk groups with titers 
below the level of detection of currently available assay systems. 
Though serological assays and techniques have provided utility in exploring basic 
epidemiological and scientific questions regarding population infection rates, the current assay 
systems routinely used require refinement and fine tuning to go beyond the current knowledge 
base and to be of adequate and consistent clinical utility, especially in populations at low risk 
of infection. 
1.5.1. Global Distribution of KSHV Infection 
The geographical distribution of KSHV infection has not been completely defined, 
though in general it has been noted that the distribution of KSHV infection matches closely the 
global distribution of KS prevalence(142).  Figure 1-7 shows KSHV prevalence worldwide 
based upon published reports.  
50
 
Legend
KSHV
0
1 - 7
8 - 17
18 - 32
33 - 54
55 - 89
Equator
Tropic of Cancer
Tropic of Capricorn
Antarctic Circle
Arctic Circle
Pacific Ocean
Atlantic Ocean
Indian Ocean
Pacific Ocean
-180° -160° -140° -120° -100° -80° -60° -40° -20° 0° 20° 40° 60° 80° 100° 120° 140° 160° 180°
0° 0°
-20° -20°
20° 20°
-40° -40°
40° 40°
-60° -60°
60° 60°
-80° -80°
80° 80°
 
Figure 1-7. Global distribution of KSHV based on studies of KSHV prevalence.  General population rates reported when 
available.  Multiple studies done in same geographic location were averaged with weighting performed based upon 
sample size.  It should be noted that a variety of different serological techniques were employed to obtain KSHV 
prevalence estimates.  Prevalence estimates are presented as percents, a value of zero percent (clear areas) have no 
available data reported. Based upon references (1, 9, 26, 27, 33, 93, 104, 123, 124, 127, 134, 139, 140, 150, 155, 171, 185, 
187, 198, 210, 212, 213, 218, 219, 226, 228, 236, 267, 270, 276, 281, 304, 309, 333, 339, 349, 354, 365, 374, 376, 382, 384, 
391, 392, 401, 404, 407, 418, 428, 430, 431, 439, 451).   
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KSHV prevalence in sub-Saharan Africa is the highest in the world (>50%)(20, 27, 33, 102, 
127, 142, 151, 155, 198, 224, 231, 260, 281, 309, 316, 328, 344, 384, 392, 401, 421, 443, 444), 
with intermediate prevalence throughout the Mediterranean (15-30%) (54, 56, 62, 63, 73, 93, 
102, 123, 155, 174, 210-212, 294, 326, 361, 362, 384, 440, 451)and low prevalence throughout 
the rest of Europe (<5%)(152, 162, 171, 191, 276, 304, 347, 375, 404).  KSHV prevalence also 
appears low in the Western hemisphere with most studies reporting seroprevalence estimates of 
less than five percent throughout North, South and Latin America(1, 28, 29, 102, 136, 174, 
236, 276, 333, 339, 350, 452).  However, recent reports demonstrate that among isolated 
populations in the Americas such as the Brazilian Amerindians, the potential for KSHV 
endemicity exists(46) with a reported prevalence of 53%.  It may be that other isolated 
populations such as Inuit populations or other Native American populations may have elevated 
KSHV seroprevalence, though studies of these types have not been reported in the scientific 
literature.  
 It is important to note that categorization of nationwide KSHV prevalence based upon 
isolated seroepidemiological studies is simply an estimate.  In some countries, such as the 
United States, it is likely that among the general population the reported prevalence of KSHV 
infection as less than 5% is accurate because numerous studies using multiple techniques have 
contributed to our understanding.  However in other countries, such as China, prevalence 
estimates are based on a few local studies using serological tests that may not have the highest 
sensitivity or specificity.  Our current understanding of the KSHV prevalence in Australia is 
based upon one unpublished report(139).   
Additionally, through epidemiological studies, we understand that country boundaries 
can be arbitrary and populations within those boundaries may not be homogenous.  For 
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instance, in Italy, seroprevalence estimates range from <10% in the North to >20% in the 
South.  Also, KSHV infection can be concentrated in certain population groups who reside in 
countries with overall low prevalence rates.  KSHV infection among homosexual males 
residing in the US may be 10 times or more higher than the rest of the population(211).   
Studies of KSHV seroprevalence are not standardized and a meta-analysis of the 
numerous studies done on KSHV infection rates has not been undertaken.  Because a gold-
standard test for KSHV does not currently exist, multiple methods have been used to define 
KSHV infection within individuals.  All of the current tests have strengths and weaknesses but 
some level of misclassification has been reported for every method described to date.   
These caveats should be noted when interpreting studies of worldwide KSHV prevalence.  
Though absolute precision of KSHV infection rates worldwide is unknown, in general it is 
accepted that Europe and the Americas are low prevalence regions, the Mediterranean 
moderate prevalence, and sub-Saharan Africa has the highest prevalence of KSHV worldwide. 
1.5.2.  Perceived Need for Improved Serological Methods for the Detection of KSHV 
 
 In an editorial commentary in the Journal of Infectious Diseases, David Hudnall points 
out some of the conflicts which arise from using different serological assays to measure KSHV 
prevalence in populations at low risk for developing KS(201).  The primary question addressed 
is whether assay sensitivity or specificity is most important when both cannot be 
simultaneously achieved through the use of one assay.  Specifically, Hudnall argues that 
immunofluorescence assays which target latent viral antigens are of use only in high risk 
groups and that through induction of lytic antigens in primary effusion cell lines prior to 
serological testing that test sensitivity can be increased.  In fact, the prevalence of KSHV was 
found to be dramatically higher (23%-29%) using the lytic assay in three studies of healthy US 
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blood donors(202, 249, 350).  This has led some to the conclusion that not only does the latent 
LANA1 IFA lack sensitivity but all other serological techniques, including ELISA assays 
targeting lytic viral epitopes present only during lytic activation, lack sensitivity as well. 
 An alternative explanation is that the lytic IFA, though highly sensitive, is of little 
utility in high or low risk populations due to its low specificity.  The low specificity and lack of 
concordance with other serological assays has been well documented(333, 350, 375) and 
reviewed in(102, 378, 379).  Because the debate continues as to the best method for defining 
KSHV seroprevalence many laboratories have chosen to work with KSHV assays with 
intermediate sensitivities and specificities.  Additionally, many groups use multiple assays to 
increase overall diagnostic accuracy, moving away from individual assays at either end of the 
sensitivity/specificity spectrum.   
 Recently authors have directly pointed out the need for seroassays which target 
multiple epitopes(241) and others have made compelling arguments for the clinical need for 
accurate diagnosis of KSHV infection(296).  Because the need for improved diagnostic assays 
for KSHV exist, and because there is no consensus as to which assays or combination of assays 
should be used to concurrently improve sensitivity and specificity, this research is designed to 
address these problems. 
 In chapter 2, research is presented which demonstrates a novel serological approach to 
improving the diagnostic capabilities of defining KSHV infection.  Gold standard KSHV 
positive and negative sera were obtained and tested using multiple serological assays.  In 
addition, the development and testing of a novel LANA1 ELISA assay is described.  A new 
method for plating sera which improves diagnostic specificity is explained and upon 
optimization of the serological method the system is validated through testing of an 
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independent gold standard set of sera.  Upon validation we conduct studies of KSHV 
seroprevalence among various populations at high and low risk of developing KS.  In addition, 
we rigorously examine our new method through testing of sera known to be cross-reactive in 
other viral ELISA assays. 
 In chapter 3, we present a case-control study of primary pulmonary hypertension (PPH) 
and KSHV infection using assays described in chapter 2.  The justification for undertaking this 
case-control study was two-fold.  First, a previous report described a strong association 
between PPH and KSHV infection using PCR and IHC on lung tissue.  A number of studies 
have shown these methods to be unreliable for diagnostic purposes and these methods have 
been responsible for a number of spurious associations with KSHV in the past.  Second, the 
epidemiology of PPH and KSHV are seemingly at odds.  Therefore, we used our serological 
assays to test whether KSHV seroprevalence was elevated among subjects with PPH compared 
to healthy controls. 
 In concluding the dissertation, a global discussion describing an overview of the 
research presented and specific strengths and weaknesses of the projects are then highlighted, 
ultimately concluding with the perceived impact of this work and what logical future work can 
be undertaken from the knowledge gained from this research. 
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2.1. Abstract 
Though substantial efforts have been made, the ability to readily and accurately 
diagnose Kaposi’s sarcoma-associated herpesvirus (KSHV, or HHV-8) in individuals remains 
a demanding task.  Sensitivities and specificities of the available diagnostic methods widely 
range and, as a matter of practicality, many are inadequate for large-scale screening studies.  
We propose here a high-throughput serological algorithm for detecting KSHV in human sera 
with high sensitivity (93%-96%) and high specificity (94%-98%).  This method is based on 
peptide based ELISAs directed against ORF K8.1 and ORF65 proteins and a newly developed 
KSHV latency associated nuclear antigen (LANA) ELISA based on purified recombinant 
antigen expressed in baculovirus. This antigen is expressed as a gluthione-S-transferase fusion 
protein which binds to glutathione-linked ELISA plates allowing the attachment of viral 
antigen to ELISA plates with high efficiency.  The validated serological algorithm is then used 
to determine seroprevalence rates among populations of particular clinical and epidemiological 
importance.  Among cadaveric renal transplant donors, from whom KSHV can be transmitted 
to uninfected recipients, we find a seroprevalence of 4.0% using a highly specific algorithm 
and 8.0% with a highly sensitive algorithm.  Among patients requiring bone-marrow 
transplantation 3.0% tested positive with the specific algorithm and 10% were positive with the 
more sensitive algorithm. We also demonstrate that patients with autoimmune disorders are 
more likely to produce false-positive KSHV ELISA test results than blood donor controls. 
Because the need for high quality KSHV detection methods are warranted and because 
questions remain about the optimal methods for assessing KSHV infection in individuals, we 
propose a systematic approach to standardize and optimize the assessment of KSHV infection 
rates using established and novel serological assays and methods.  
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2.2. Introduction 
Since the discovery of Kaposi’s sarcoma-associated herpesvirus (KSHV)(100), also 
known as human herpesvirus 8 (HHV-8), the virus has been implicated in diseases of the 
immunocompromised host including Kaposi’s sarcoma (KS), multicentric Castleman’s disease 
and primary effusion lymphoma(295).  In the US, among immunocompromised individuals 
who are KSHV infected, the life-time risk of developing KS is 20-30%(78, 165, 275, 310, 
356).  With a prevalence of 3-10%(78, 333) among iatrogenically immunosuppressed patients 
and 20-40% among HIV-infected individuals(141, 174, 179, 227, 324), KSHV is clearly of 
significant public health concern in the US.  In regions of Africa where endemic infection can 
exceed 60%(343), the morbidity and mortality associated with KSHV related sequelae are of 
even greater concern. 
Significant morbidity and mortality are associated with a diagnosis of KS among 
transplant recipients. In one study of liver transplant recipients, 100% of KSHV negative 
recipients who received a KSHV-infected allograft seroconverted within 6 months post-
transplantation.  Of those, 50% developed KS and died of multiorgan failure within 1 year 
post-transplantation (268).     
Among kidney transplant recipients seropositive for KSHV prior to transplantation 
23%-28% develop KS(92, 165).  A similar rate has been reported among heart transplant 
recipients where 25% of KSHV positive recipients developed KS (149).  In addition to 
infection prior to transplantation, recipients can acquire KSHV from infected donor organs(30, 
256, 268, 288, 308, 326, 356).  Though the exact viral transmission efficiency via this route is 
unknown, the probability of seronegative transplant recipients becoming infected with KSHV 
through infected renal allografts has been estimated to be 2%-12%(288, 356).  In addition, 
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recipients of bone marrow transplants who are infected with KSHV infection are at increased 
risk of bone marrow failure.  Regardless of whether the virus is acquired before or after 
immunosuppression, it is clear that both primary infection with and reactivation of KSHV 
dramatically increases the risk of malignant and nonmalignant disease among HIV-infected 
individuals and transplant recipients(137, 220, 255, 257, 259, 278).   
A recent study conducted in the US demonstrates that transfusion-associated 
transmission is likely to occur and estimates the KSHV transmission risk per transfused 
component is around 0.1%(136).  Though the effective transmission rate of infection is low, 
the number of transfusions per year is high.  The American Association of Blood Banks 
estimates that approximately 5 million transfusions occur in the US each year(11).  Based upon 
these estimates, up to 5,000 cases of transfusion-associated KSHV infections can be expected 
to occur every year in the United States.   
Though the existence of KSHV has been recognized for over a decade(100) definitive 
diagnosis of viral infection remains a challenge.  Some of the factors which make definitive 
diagnosis difficult include: a large proportion of KSHV infected individuals do not have 
detectable levels of KSHV DNA in peripheral blood (302), concordance between serological 
assays targeting different antibodies varies(437), and assembling a known uninfected cohort 
with 100% certainty is not possible(237, 274).   
 Serologic tests for KSHV were first developed for reactivity to the KSHV latency 
associated nuclear antigen (LANA)(173, 174, 301).  These assays were performed by indirect 
immunofluorescence (IFA)(227) or western blot assays using infected cell lines(173). While 
the LANA IFA is highly specific for KSHV infection, its sensitivity is only approximately 
80%,(174) resulting in high rates of false-negativity.  Further, IFAs are cumbersome and 
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cannot be used for high-throughput screening, disadvantages that apply to an even larger extent 
for Western blot assays. 
In addition to the LANA IFA, other serologic tests have been developed against KSHV 
lytic antigens including enzyme-linked immunosorbent assays (ELISA) targeting structural 
antigens.  Unlike latent antigens, structural antigens are highly conserved among herpesviruses 
resulting in substantial cross-reactivity and high false positivity rates(249).  Whole cell lytic 
antigen assays measure KSHV seroreactivity, but this seroreactivity can also be partially 
absorbed by non-KSHV infected cell lysates demonstrating that seroreactivity to whole cell 
lytic antigens can be nonspecific(174, 249, 301).   Attempts have been made to produce a 
recombinant LANA1 protein (rLANA1), but marked loss of sensitivity has been noted(318).    
One approach to increase assay specificity for KSHV lytic antigens has been to use 
recombinant protein ELISAs.  Both whole structural antigens and immunodominant peptides 
have been evaluated in an ELISA format(375, 400). These tests have improved sensitivity and 
specificity characteristics compared to the whole cell lytic IFA(115, 156, 209, 333) though at 
present, no single recombinant antigen assay has sufficient sensitivity/specificity 
characteristics for use in routine clinical screening.  Optimal detection of KSHV seropositivity 
appears to require use of both latent and lytic antigens which are independently screened and 
scored for seroreactivity.   
Because of the need for high quality KSHV detection methods, we used a systematic 
approach to standardize and optimize the assessment of KSHV infection rates using established 
and novel serological assays and methods.  Upon validating our assay algorithm we examined 
seroprevalence rates among high-risk populations of clinical interest including transplant 
donors and patients with autoimmune disease who may generate false positive results.   
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2.3. Materials and Methods 
2.3.1. Subjects 
Initial assay evaluation was performed on 90 case patient sera obtained from persons 
with biopsy-confirmed KS.  Sera were drawn within 12 months after KS diagnosis and all case 
subjects were HIV infected males with a diagnosis of AIDS.  Case sera were collected from 
May of 1990 to May of 2004.  Control sera (100) were obtained from New York City Blood 
Bank (NYCBB) donors, all of whom had previously been screened and found to be LANA IFA 
seronegative, as well as negative for HIV, HCV, HBV, syphilis and HTLV1.  Control sera 
were collected throughout 1991.  A second independent set of case and control sera were tested 
for purposes of validating our assay algorithm.  Case sera for the independent test set, a total of 
87, were obtained from two large longitudinal studies of HIV-infected men (241, 381) and 
defined as sera drawn from subjects after a clinical diagnosis of KS.  These case sera were 
collected from 1985 to 2002.  Control sera for the test set were an additional 100 blood donors 
from the NYCBB. 
 Sera from patients with severe aplastic anemia and myelodysplastic syndrome, 
collected from 1992-2000, were obtained from the National Marrow Donor Program (NMDP) 
and matched with respect to age, gender and history of blood transfusion.  Screened cadaveric 
renal transplant donor sera were obtained from the Center for Organ Recovery and Education 
(CORE), Pittsburgh Pennsylvania.   
Sera from patients with systemic lupus erythematosus (SLE) (5 male, 45 female) were 
obtained from the University of Pittsburgh Division of Rheumatology and Clinical 
Immunology and 50 blood donor controls were obtained from the NYC blood bank.  Sera from 
SLE patients were collected from 2001-2003.  Prior to KSHV testing, case and control 
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specimens, as well as 5 positive laboratory controls from the University of Pittsburgh Cancer 
Institute (UPCI) were blinded.   Informed consent from all study participants and IRB approval 
were obtained in accordance with the guidelines for human experimentation of the University 
of Pittsburgh. 
2.3.2. Serological testing  
 Sera were tested by using ELISA serological assays against recombinant baculovirus 
expressed LANA1 and against peptide-based ELISAs for ORF65 and K8.1 antigens.  In 
addition, sera from patients with SLE were tested using a LANA1 immunofluorescence assay 
(IFA).  For the ELISA assays, serum at a dilution of 1:100, was added to 4 wells: two coated 
with peptide (5 µg/µl) and the remaining 2 wells without peptide. Optical density (OD) values 
were read on a Dynatech Laboratories (Chantilly, VA) MRX 1CXA0716 plate reader at 405nm 
wavelength after reaction with rabbit anti-human IgG HRP (1:6000, DAKO, Carpinteria, CA) 
and development in 3,3’,5,5’-tetramethylbenizidine (BioRad, Hercules, CA) .   
ODs for a given sample were calculated as the mean OD of the wells containing 
peptide minus the mean OD of the wells containing no peptide (see Figure 1).  All samples in 
the study were each independently tested in duplicate and all serological testing was done in a 
blinded fashion.  Blinding was maintained until the completion of all serological testing.     
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Figure 2-1.  Enzyme-Linked Immunosorbent Assay (ELISA) plating scheme. 
Each sample tested has two wells coated with antigen (indicated by gray shading in columns 
1,2,5,6,9 and 10) and two wells that are not coated with antigen (unshaded circles of columns 
3,4,7,8,11 and 12). The average of the non-coated wells, used as a background correction, is 
subtracted from the average of the peptide-coated wells to give the adjusted optical density. 
 
 
 
 
2.3.3. K8.l and ORF65 peptide ELISAs 
Antibody testing was performed using enzyme-linked immunosorbent assays (ELISA) 
based on peptides from the open reading frames (ORF) 65 and K8.1 with sequences; 
ASDILTTLSSTTETAAPAVADARKPPSGKKK and 
RSHLGFWQEGWSGQVYQDWLGRMNCSYENMT respectively as previously described 
(329, 400) with the modifications noted above.  
2.3.4. rLANA1-GST ELISA 
ORF73 recombinant baculovirus was produced via transfection with a pDEST20 
plasmid vector (Invitrogen, Carlsbad, CA) containing GST-fused full length LANA1 protein. 
Sf9 cells were grown in BacPak complete medium (Clontech BD-Biosciences, Palo Alto, 
California) on a shaker at 135 rpm in a 27ºC incubator.  At the time of infection, the 
concentration of cells was adjusted to 1x106 cells/ml, spun down, and resuspended in 1/10 of 
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the total volume of unsupplemented medium.  Baculovirus was used to infect the cells at a 
multiplicity of infection equal to one for 45 minutes at room temperature.  Supplemented 
BacPak medium was added to full volume and the infected cells were incubated for 3 days at 
27ºC prior to harvest. The cells were pelleted, frozen in an ethanol-dry ice bath and thawed in a 
solution of 10mM TrisHCl pH7.5, 130mM NaCl, 10mM NaF, 10mM sodium phosphate, 
10mM sodium pyrophosphate, and 1% Triton X-100 with protease inhibitors Aprotinin (Roche 
#236 624), Leupeptin (Roche #1 017 101), Pepstatin (Roche #1 359 053), and PMSF (Sigma-
Aldrich, St. Louis, MO) added just prior to use. The lysed cells were spun down and the 
supernatant was collected and purified using 1ml glutathione sepharose beads (Amersham, 
Piscataway, NJ) per 5ml of cell lysate. The purified GST-LANA1 was eluted with a solution of 
20mM glutathione (Sigma-Aldrich, St. Louis, MO) in 50mM Tris pH 8.0, in three fractions of 
1ml each. The first two fractions were combined into a pooled stock with a final concentration 
of 0.4ug/ul.   
Reacti-bind glutathione plates were used according to the manufacturer-provided 
protocol (Pierce, Rockford, IL). Plates were washed 3 times (200µl/well) with 1X PBS/0.05% 
Tween 20.  Purified GST-LANA1 protein was diluted in wash buffer (0.018µg/µl) and added 
to the wells at a volume of 110ul.  Plates were covered and left to incubate at room temperature 
for 1 hour and washed 3 times with 200ul wash buffer per well.   
To measure anti-LANA1 antibodies, serum was added at a 1:100 dilution in 5% milk 
buffer, covered and incubated 1 hour at room temperature. Rabbit anti-human IgG HRP-
conjugated antibody was diluted 1:6000 in 5% milk buffer and 100ul/well was added and 
incubated for 1 hour at room temperature.  A colorimetric detection was performed as 
described for the peptide ELISAs. 
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2.3.5. LANA1 Immunofluorescence Assay 
The LANA1 IFA was performed as previously described(174, 240).  Two independent 
readers scored each sample.  Two discordants occurred and were resolved by a third reader. 
2.4. Results 
2.4.1. Recombinant LANA1-GST ELISA Development and Optimization 
Previous efforts to develop a recombinant LANA1 ELISA (rL) have been plagued by 
low test sensitivity.  Initially, Olsen et al. mapped ORF73 (LANA1) for peptides which could 
potentially be used in an ELISA format but the sensitivities of the products were low (11%-
44%)(318). Using the Semliki Forest virus system, Corchero et al. produced KSHV LANA for 
use in an ELISA format(115) though they found that it was of less utility than lytic assays. 
We hypothesized that this low sensitivity may be in part to poor retention of antigen on 
plates due to the unusual charge structure of the LANA protein.  To address this possibility, we 
generated a baculovirus-expressed LANA1-GST (rL-G) fusion protein which was coated to 
glutathione-linked 96-well plates.  Using a mouse monoclonal antibody to LANA1, GST-
LANA1 retention on glutathione plates was found to be approximately 20-30% greater than 
standard ELISA plates (data not shown).  Increased seroreactivity is seen when patient sera 
were examined (Figure 2).  
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Figure 2-2.  Optical density values – sera from patients infected and uninfected  
with KSHV plated on glutathione ELISA plates versus standard ELISA plates. 
 
In all but one KS sera, OD values are higher on the glutathione plates, while no 
significant increase in reactivity is observed among the control sera.  Using dilutions of rL-G 
among seroreactive and non-reactive serum samples, 1.0µg was found to give the maximum 
seroreactivity among the case sera with no appreciable reactivity observed among the control 
sera (Figure 3). 
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Figure 2-3. Optical density values observed from patients infected and uninfected with KSHV at differing 
concentrations of LANA1.  The final concentration used was 1 µg/well. 
 
2.4.2. KSHV Multi-antigen Algorithm 
 The rLG ELISA was evaluated together with the previously developed ORF65 and 
K8.1 ELISAs(400).  In this analysis, 90 KS patient sera were compared to 100 blood donor 
sera.  As seen in figure 4, case and control sera show significant overlap in optical densities for 
each of the three individual antigens.  The rL-G ELISA shows highest specificity at very low 
OD values, while the K8.1 assay is the best discriminator overall when assessing the assays 
independently.   
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Figure 2-4.  Distribution of optical density values among blood donors (closed circles) and 
subjects with Kaposi’s sarcoma (open circles) for K8.1 (panel A), ORF65 (panel B), and 
LANA1 (panel C) enzyme-linked immunosorbent assays. 
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Figure 2-5.  Reciever Operator Characteristic (ROC) curve of individual assay performance.  
Symbols indicate sensitivity and specificity of assays at differing optical density values. 
 
Specificity
Se
ns
iti
vi
ty
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
K8.1
ORF65
LANA1
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
OD = 0.05
OD = 0.05
OD = 0.01
OD = 0
OD = 2.8
 
To determine the optimal discriminator cut-off value for each assay alone, the data 
were plotted in a receiver operator characteristic curve (Figure 5).  Based on the results of 
individual assays, we performed multiple iterations of OD cut-off values to obtain two 
algorithm models: one that maximizes sensitivity and one that maximizes specificity, while not 
allowing either value to drop below 90%.   
Based upon these calculations a specimen was classified as positive if either the K8.1 
assay OD was greater than 0.045, the ORF65 was greater than 0.0573 or LANA1 OD was 
greater than 0.041.  This algorithm yielded a sensitivity of 95.6% and a specificity of 94.0% 
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(Table 1, panel A).  For the high specificity algorithm, a model was chosen where specimens 
were classified as positive if either the K8.1 assay OD was greater than 0.045, the ORF65 was 
greater than 0.155 or LANA1 OD was greater than 0.048.  This algorithm yielded a sensitivity 
of 93.3% and a specificity of 98.0% (Table 1, panel B).
  Table 2-1.  Training set contingency table and multi-assay sensitivity and specificity.    
A. High Sensitivity Algorithm
  
True Status 
 
 KS+ BD  
KSHV+ 86 6 92 
KSHV – 4 94 98 
 
Te
st
 R
es
ul
t 
 90 100 190
     
 
 
 
 
 
 
 
 
 
 
Sensitivity = 956.0
90
86 =  
 
Specificity = 94.0
100
94 =  
 
 
 
 
 
 
 
 
 
B. High Specificity Algorithm
  
True Status 
 
 KS+ BD  
KSHV+ 84 2 86 
KSHV – 6 98 104
 
Te
st
 R
es
ul
t 
 90 100 190
     
 
 
 
 
 
 
 
 
 
 
Sensitivity = 933.0
90
84 =  
 
Specificity = 98.0
100
98 =  
 
 
 
 
 
 
 
 
 
 
 
Panel A. values based on serological algorithm where a specimen is classified as positive if the optical 
density is greater than 0.045 for the K8.1 assay or >0.0573 for the ORF65 assay or >0.041 for the 
LANA1 assay.  Panel B. values based on serological algorithm where a specimen is classified as 
positive if the optical density is greater than 0.045 for the K8.1 assay or >0.155 for the ORF65 assay or 
>0.048 for the LANA1 assay.   
 
To validate the multi-assay algorithms, an independent test set of case and control sera 
were evaluated (Figure 6).  Among the 100 new blood donor sera we observed a specificity of 
94% and 97% with the sensitive and specific algorithms respectively.  Among the 87 KS 
patient sera, the sensitivity dropped to 85.1% using the highly specific algorithm but remained 
at 93.1% with the more sensitive model. 
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Figure 2-6.  Selection Method for Determination of High Sensitivity and High Specificity Assay 
Algorithms.   
To evaluate the rLG, ORF65 and K8.1 ELISAs, and because specimens were received 
from multiple repositories, we examined the integrity of the sera subjected to multiple freeze-
thaws (Figure 7).  All assays showed a statistically significant linear decrease in optical density 
(OD) with repeated freeze-thaws (P<0.01).  The total percentage decrease in signal intensity 
from the first measurement to the last was 13.6% for the ORF65 assay, 25.2% for LANA1, and 
60.0% for K8.1, suggesting that handling can affect KSHV assay performance, but under most 
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conditions with proper handling, freeze-thaw cycles are unlikely to account for significant loss 
of seroreactivity.  
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Figure 2-7.  The effects of multiple freeze thaws on a human sero-reactive serum  
sample. Panel A. One patient sera seroreactive for ORF65, LANA1 and K8.1 was frozen and 
thawed a total of 22 times and tested on each assay.  Panel B. Linear Regression of samples 
from panel A.   
 
2.4.3. Serosurvey of Cadaveric Renal Transplant Donors 
Because transmission of KSHV can occur from an infected kidney donor to an 
uninfected recipient, the optimized assay algorithms were used to test 50 screened sera from 
US renal transplant donors.  Using the highly specific algorithm, overall seroprevalence was 
low at 4.0% (2/50) similar to the 2.8% (7/250) observed among US blood donors tested in this 
study (P=0.46) (Table 2).  The odds ratio (OR) associated with this comparison is 1.4 and the 
95% confidence interval (CI) ranges from 0.14 to 7.9.  The more specific algorithm identified 
8.0% (4/50) of the kidney donors as KSHV infected, though when compared to the 6.4% 
(16/250) found among blood donors with this method, no significant difference was observed 
between the groups (P=0.43; OR=1.3; CI=0.41,4.0). 
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Table 2-2.  Comparison of seroprevalence of KSHV in different populations with a high sensitivity 
algorithm versus a high specificity algorithm 
 
  High Sensitivity Algorithm  High Specificity Algorithm 
 
Population 
Sample 
Size 
 
Seroprevalence
 
P-value 
  
Seroprevalence 
 
P-value 
Blood Donors – 
Training Set 
 
 
100 
 
6.0% 
 
----- 
  
2.0% 
 
----- 
Blood Donors – 
Test Set 
 
 
100 
 
6.0% 
 
0.62 
  
3.0% 
 
0.50 
Blood Donors – 
SLE Controls 
 
 
50 
 
8.0% 
 
0.43 
  
4.0% 
 
0.41 
Cadaveric Renal 
Transplant Donors 
 
 
50 
 
8.0% 
 
0.43 
  
4.0% 
 
0.41 
Severe Aplastic 
Anemia 
 
 
50 
 
10.0% 
 
0.27 
  
4.0% 
 
0.41 
 
Myelodysplastic 
Syndrome 
 
 
50 
 
10.0% 
 
0.27 
  
2.0% 
 
0.71 
Systemic Lupus 
Erythematosus 
 
 
50 
 
24.0% 
 
0.002 
  
20.0% 
 
0.0003 
       
 
KS Patients 
(Training set) 
 
 
 
90 
 
 
95.6% 
 
 
---- 
  
 
93.3% 
 
 
----- 
KS Patients  
(Test set) 
 
87 
 
 
93.1% 
 
0.35 
  
85.1% 
 
0.06 
Note:  P-values are Fishers exact and computed with US blood donors in training set as the referent 
group for low risk populations and subjects with KS in the training set as the referent group for 
comparisons in the high risk populations. 
 
 
2.4.4. KSHV Case-Control Study of Patients with Myelodysplastic Syndrome and Severe 
Aplastic Anemia 
 Among subjects requiring bone marrow transplantation the overall seroprevalence was 
3.0% for the more specific model and 10.0% for the sensitive model and did not significantly 
differ from that observed among blood donors (P=0.4) (Table 2).  In addition, KSHV 
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seroprevalence did not significantly differ between patients with severe aplastic anemia (4%) 
and patients with myelodysplastic syndrome (2%) using the more specific method (OR=2.0; 
95% CI=0.10 - 122.9; and P=0.50) or with the more sensitive method, where both groups had 
an equivalent KSHV seroprevalence of 10%.   
2.4.5. Case-Control Study of Patients with SLE and Blood Donor Controls 
In using a case-control study design among 50 patients with SLE and 50 blood donors, 
our study objectives were two-fold; first, to rigorously test the utility of our assay system using 
a patient population known to produce false positive viral ELISA tests, and second to 
accurately identify the rate of KSHV infection among patients at increased risk of being on a 
course of immunosuppressive therapy, an important risk factor for KS.  Our a priori null 
hypothesis was that KSHV seroprevalence among subjects with SLE and blood donor controls 
would be equivalent.  However, using our ELISA assays, we observed a significantly higher 
KSHV seroprevalence among the SLE patients using the more specific algorithm (OR=6.0; 
95% CI, 1.2-29.0) and the more sensitive algorithm (OR=3.6; 95% CI, 1.1-12.2). 
Median OD values among SLE patients were significantly elevated compared to blood 
donors for the LANA1 assay (p=0.02) and the K8.1 assay (p=0.01).  This trend was observed 
for ORF65 but did not reach a level of statistical significance (p=0.18).  Based upon our more 
specific ELISA serological algorithm, of the 10 positive SLE samples, none were ORF65 
positive, four were K8.1 positive only, six were LANA1 positive only, and one specimen was 
classified positive by K8.1 and LANA1.  To further explore the apparent KSHV seroreactivity 
among patients with SLE, the LANA-1 immunofluorescence assay (IFA) was utilized.   
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Patient With KS
SLE Patient
Human Sera DAPI
SLE Patient
 
Figure 2-8.   Representative IFA examples from KSHV-infected subject with KS and from two 
SLE patients with seroreactive ELISA results.   
 
 
Figure 2-8 shows representative IFA examples from a KSHV-infected individual with 
KS and from two SLE patients.  Note the increased level of background staining among the 
SLE patients but the lack of specific nuclear staining, indicative of KSHV positivity, which is 
observed in the positive control sample.  
74
 
2.5. Discussion 
 Past reports have suggested that KSHV testing using multiple serological assays(274) 
or seroassays which target multiple epitopes(241) are needed to achieve maximal sensitivity.   
We have demonstrated the potential to increase KSHV detection accuracy rates beyond what 
has been previously reported through the combined use of established and novel assays.  
 In conducting this research we demonstrate the ability to target a KSHV latent viral 
antigen in an ELISA format.  We utilized a glutathione-s-transferase tag and glutathione 
ELISA plates which allowed for the attachment of our recombinant LANA1 protein to the 
plates with high efficiency.  As an independent assay, the sensitivity and specificity of the rL-
G ELISA is similar to that observed for the LANA1 IFA but with significantly higher 
throughput.  In addition, as one component of a multi-assay algorithm, the assay provides 
unique information which increases sensitivity beyond what is observed using an independent 
lytic-based ELISA.   
By making minor adjustments in the OD cut-off values in the multi-assay algorithm we 
are able to present our results in comparative models that favor sensitivity or specificity.  We 
have demonstrated that the relations in the case-control studies remain relatively constant even 
with minor changes in assay sensitivity and specificity (based upon p-values and odds ratios).  
Though the more sensitive algorithm definition consistently identified more seropositives, no 
significant difference in the ratio of positives to negatives was observed between the two 
different systems for any study population.   
For screening efforts high sensitivity is often desired, however for an assay to provide 
clinical utility, high specificity must be achieved.  The need for clinical testing of KSHV has 
been addressed in the past (286, 296) and the KSHV algorithms proposed here achieve this 
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high level of specificity (94%-98%).  Among all US blood donors in the study 2.8% were 
observed to be KSHV infected with the algorithm designed for higher specificity and 6.0% 
when evaluated with the algorithm designed for higher sensitivity.  It should be noted that an 
absolute evaluation of assay specificity is not possible when using US blood donors as a gold-
standard negative population.  US blood donor prevalence has been estimated to be 2-4%(333), 
therefore it can be reasonably expected that some proportion of the 2-6% of seropositive blood 
donors observed in this study are actually infected with KSHV, which could increase the 
overall specificity of both algorithms. 
 Epidemiologically it is somewhat implausible to suppose that KSHV infection is three 
to six times greater among patients with SLE compared to blood donors.   We have provided 
evidence here of the potential that exists for false positive KSHV tests among SLE patients.  
As an alternative to the ELISA tests, we utilized a LANA1 IFA which visibly revealed the 
increase in non-specific antibody reactivity.  Though the LANA1 IFA may be impractical for 
large-scale population screening, it can be reliably expected to produce accurate results among 
patient groups at increased risk of producing erroneous results among standard KSHV ELISA 
tests.  Therefore, medical screening which assesses factors such as whether a patient has SLE 
or perhaps other autoimmune disorder can be used as one component in determining the type 
of KSHV testing algorithm that would best increase KSHV diagnostic specificity. 
 In conclusion, we describe a novel serological approach for defining KSHV 
seropositivity which has high sensitivity and specificity.  Additionally, we present KSHV 
seroprevalence estimates of populations of particular clinical importance.  Substantial evidence 
exists to suggest that KSHV can be transmitted to low risk populations through blood 
transfusion(47, 136) and organ transplantation (254) where a proportion will go on to develop 
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KSHV-related morbidity and mortality. KSHV screening of transplant donors and recipients 
could potentially prevent cases of KS from developing, aid in earlier diagnoses of KS that do 
develop, reduce non-KS morbidities associated with KSHV, and potentially block one of the 
viral transmission pathways of KSHV.    The serological methods presented here may provide 
a mechanism to address these issues in the future. 
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3. Kaposi sarcoma associated herpes virus and primary and secondary pulmonary 
 hypertension. 
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3.1.  Abstract 
Background: Kaposi’s sarcoma-associated herpesvirus (KSHV) has been implicated as a 
factor in the pathogenesis of primary pulmonary hypertension (PPH).  We conducted a case-
control study of patients with PPH and pulmonary hypertension associated with other disorders 
(secondary PH) to look for evidence of KSHV infection.   
Materials and methods: The study population was comprised of patients diagnosed with 
pulmonary hypertension at the University of California San Francisco (UCSF) Medical Center 
Department of Cardiology between July and November 2003. Serological testing for KSHV 
was performed using enzyme-linked immunosorbent assays (ELISA) based on peptides from 
the open reading frames (ORF) 65 and K8.1, using sera from 19 patients diagnosed with PPH, 
29 patients with secondary PH, and 150 control subjects 
Results:  The overall seroprevalence of KSHV among all study participants was 2.0%.  The 
rate among controls was 0.7% (1/150), and among the study participants with PPH we found 
no evidence of KSHV infection (0/19).  There was no significant difference between the 
observed seroprevalence of KSHV among subjects with PPH compared to controls (P=0.89).  
Of the 29 subjects diagnosed with secondary PH, 3 (10.3%) were KSHV seropositive. 
Significantly, 2 of the 3 KSHV-infected secondary PH patients were also HIV positive – which 
is a known independent risk factor for both KSHV infection and secondary PH.   
Conclusion:  Our data do not support KSHV infection as playing a significant role in PPH or 
non-HIV-associated secondary PH compared to age and gender matched control subjects. 
 
Keywords:  Pulmonary hypertension, Kaposi’s sarcoma-associated herpesvirus, KSHV, HHV-
8, K8.1, ORF65, ELISA 
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Abbreviations: 
COPD:  Chronic obstructive pulmonary disease 
ELISA:  Enzyme-linked immunosorbent assay 
HHV-8:  Human herpesvirus 8 
HIV:  Human immunodeficiency virus 
IFA:  Immunofluorescence assay 
IHC:  Immunohistochemistry 
KSHV:  Kaposi’s sarcoma-associated herpesvirus 
MCD:  Multicentric Castleman’s disease 
OD:  Optical density 
ORF:  Open reading frame 
PCR:  Polymerase chain reaction 
PEL:  Primary effusion lymphoma 
PH:  Pulmonary hypertension 
PPH:  Primary pulmonary hypertension 
UCSF:  University of California San-Francisco 
UPCI:  University of Pittsburgh Cancer Institute 
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3.2. Introduction 
Pulmonary hypertension (PH) is a progressive disorder characterized by elevated mean 
pulmonary-artery pressure which may result in right ventricular failure. Primary pulmonary 
hypertension (PPH) is idiopathic, whereas secondary PH results from other conditions known 
to increase pulmonary artery pressure.(48, 369)  PPH is most prevalent in persons 20 to 40 
years of age and is 3 times more frequent in women than in men.  This has led some to 
hypothesize that hormonal dynamics or an X-linked genetic locus may be involved with 
disease development.(253)  More recently, it has been reported that infection with Kaposi 
sarcoma associated herpesvirus (KSHV), also known as human herpes virus type 8 (HHV-8), 
is associated with PPH.(110)  That an infectious agent may play an etiologic role in this 
heretofore idiopathic disorder is an intriguing hypothesis that has potentially profound 
implications for its diagnosis, prevention, and treatment.   
Since the discovery of KSHV in 1994,(100) a number of diseases and disorders have 
been hypothesized to be associated with KSHV.  However to date, scientific consensus as to 
the diseases in which KSHV plays an etiologic role are limited to Kaposi’s sarcoma (KS), 
primary effusion lymphoma (PEL), and a subset of  multicentric Castleman’s disease 
(MCD).(380)  Epidemiologic studies have described potential modes of viral transmission,(77, 
275, 330, 344, 356) rates of infection in different populations(1, 49, 99, 152, 211, 213, 227) 
and demographic and social risk factors associated with KSHV.(24, 27, 49, 77, 83, 118)  
Because KSHV is a relatively new virus, much is still unknown regarding its role as a potential 
etiologic agent or cofactor in diseases other than KS, PEL, and MCD.  It is plausible that a 
number of rare idiopathic disease states could have a viral etiology or be influenced by a viral 
agent such as KSHV.  
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As the reported association between PPH and KSHV has been questioned,(193) we 
sought to examine whether an association exists between PPH and secondary PH and KSHV 
infection in a robust manner, using different methods than those previously employed.  We 
designed a matched case-control study with sufficient power to examine whether KSHV 
infection differed between individuals with and without PH using highly specific and sensitive 
serological assays based on both lytic and latent KSHV antigens. 
3.3 Materials and Methods 
3.3.1. Subjects 
 The study population was comprised of patients diagnosed with pulmonary 
hypertension at the University of California San Francisco (UCSF) Medical Center Department 
of Cardiology between July and November 2003. Pulmonary hypertension was defined as right 
heart catherization by a mean pulmonary artery pressure greater than 25 mmHg at rest.  To 
elucidate the etiology of the PH and segregate patients to the PPH group and the secondary PH 
group, patients underwent diagnostic studies including echocardiography, ventilation- 
perfusion scans, pulmonary function testing, and blood sampling to evaluate for the presence 
of collagen vascular disease, liver disease, thyroid disease, and HIV.  High resolution CT 
scanning, sleep studies, and coronary angiography were performed as indicated by the history 
and physical exam.  
The PPH group included patients with idiopathic pulmonary hypertension without a 
demonstrable cause or association. The secondary PH group was comprised of all other 
patients who met the above definition for PH.   In total, the study population included 19 
subjects with PPH, 29 subjects with secondary PH (Table 3-1) and 150 controls (130 healthy 
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individuals, 19 with coronary artery disease and 1 with meningioma).  Controls were matched 
to cases with respect to gender and age (+/- 5 years).    
Prior to patient selection, sample size calculations were performed to establish the 
minimum sample size required to observe a significant difference in infection rates between 
cases and controls.  Assuming the KSHV infection rate among patients with PPH was 32%, 
half the rate previously reported,(110) and the rate among controls was 3.3%, the rate of 
KSHV seroprevalence observed among US blood donors,(333) a minimum sample size of 19 
cases and 57 controls should allow a significant effect to be observed between cases and 
controls with 95% confidence and 80% power.  If the actual rate of KSHV infection among 
patients with PPH is 63% as reported by Cool et al., then our sample size should allow a 
significant effect to be observed between cases and controls with 99% confidence and 99% 
power. 
Blood was drawn from each subject and serum was separated and frozen at –70o 
Celsius. Prior to KSHV testing, case and control specimens, as well as 10 positive and 10 
negative laboratory controls from the University of Pittsburgh Cancer Institute (UPCI) were 
blinded.  The blinding was performed and maintained by UCSF until the completion of all 
serological testing at UPCI.  Informed consent was obtained from all study participants and 
IRB approval obtained in accordance with the guidelines for human experimentation of the 
University of California San Francisco and the University of Pittsburgh. 
3.3.2. Serological testing and definition of algorithm for defining KSHV seropositivity  
Antibody testing was performed using enzyme-linked immunosorbent assays (ELISA) 
based on peptides from the open reading frames (ORF) 65 and K8.1 with sequences; 
ASDILTTLSSTTETAAPAVADARKPPSGKKK and RSHLGFWQEGWSGQVYQDWLGRMNCSYENMT 
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respectively as previously described (329, 400) with modifications. In brief, serum at a dilution 
of 1:100, was added to 4 wells: two coated with peptide (5 µg/mL) and the remaining 2 wells 
without peptide. Optical density (OD) values were read on a Dynatech Laboratories (Chantilly, 
VA) MRX 1CXA0716 plate reader at 405nm wavelength after reaction with rabbit anti-human 
IgG HRP (1:6000, DAKO, Carpinteria, CA) and development in 3,3’,5,5’-
tetramethylbenizidine (BioRad, Hercules, CA) .  ODs for a given sample were calculated as the 
mean OD of the wells containing peptide minus the mean OD of the wells containing no 
peptide.  
The assay cutoff for each peptide was determined a priori to be 0.04 based upon 
receiver operator characteristic curve analyses.  Specimens were considered positive if the OD 
of both ELISA assays was greater than 0.04, negative if both assays had ODs less than or equal 
to 0.04 and equivocal if the two assays were discordant. Concordance for the ELISA assays 
was 96% (Figure 3-1) and all internal controls were correctly identified by both assays.  
Samples with discordant ELISA results (positive for one antigen and negative for the other) 
were retested using an indirect immunofluorescence assay (IFA) as previously described.(174)  
Patients reactive in 2 of the 3 seroassays were classified as KSHV seropositive. The algorithm 
for defining seropositivity was determined to be 99% specific and 88% sensitive based upon 
quality control panels (data not shown).  To elucidate the relationship between KSHV and PPH 
and secondary PH, the following statistical tests and measures of association were utilized 
where appropriate; Fisher’s exact test, Student’s t-tests, exposure odds ratios, and exact 95% 
confidence limits. 
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3.4. Results 
 Cases and controls were similar with respect to age and gender; and at time of 
enrollment, patients with PPH and secondary PH had similar pulmonary artery pressures 
P=0.35 (table 4-1).   
 
 
Table 3-1. Demographic and clinical characteristics of study subjects. 
 
 
 
 
PPH (N=19) 
  
Secondary PH (N=29) 
 Controls 
(N=150) 
 
 Characteristic  
Number(%) 
  
p-val 
  
Number(%) 
  
p-val 
  
Number(%) 
 
 Gender 
    Male 
    Female 
 
 
5 (26.3) 
14 (73.7) 
 
 
 
 
0.29†
  
12 (41.4) 
17 (58.6) 
 
 
 
 
0.36†
  
54 (36.0) 
96 (64.0) 
 
 Ethnicity 
      White 
      Black 
      Hispanic 
      Asian  
 
 
11 (57.9) 
2 (10.5) 
3 (15.8) 
3 (15.8) 
 
 
 
 
 
0.01†*
  
13 (44.8) 
3 (6.9) 
9 (31.0) 
4 (17.2) 
 
 
 
 
 
<.001†*
  
127 (84.7) 
2 (1.3) 
8 (5.3) 
13 (8.7) 
 
  Mean ± sd    Mean ± sd    Mean ± sd  
  
Age  
 
 
47.4±15.5 
 
  
0.44‡
  
50.9±10.1 
  
0.69‡
  
49.9±13.1 
 
 Mean PA pressure 
(mmHg) 
 
 
46.4±14.5 
    
42.4±14.0 
  
0.35‡+
  
---- 
 
          
Note:  P-values calculated using controls as referent group.  PPH, primary pulmonary hypertension; 
PA, pulmonary arterial; †Fisher’s exact one-sided p-value; *P-values calculated as “White” versus “non-
White”; ‡Student’s T-Test, pooled variance estimator. +Comparison is PPH versus secondary PH, PA 
pressure not available for control subjects. 
 
The overall seroprevalence of KSHV among all study participants was 2.0%.  The rate among 
controls was 0.7% (1/150), and among the study participants with PPH we found no evidence 
of KSHV infection (0/19) (Table 3-2).  Of the 29 subjects diagnosed with secondary PH, 3 
(10.3%) were KSHV seropositive (2 with PAH secondary to HIV infection and 1 with 
scleroderma).     
 
85
 
There was no significant difference between the observed seroprevalence of KSHV 
among subjects with PPH compared to controls (P=0.89) or patients with secondary PH 
(P=0.21).  A significant KSHV association was present between subjects with secondary PH 
and controls (P=0.01) with an odds ratio of 17.3 and 95% confidence interval of 1.3-908.   
 
 
Table 3-2.  Subjects seropositive for Kaposi’s sarcoma-associated herpesvirus by   
                   assay 
 
 Subjects                
  
Number
 K8.1 
positive 
 ORF65 
positive 
 KSHV 
positive 
 
 
 
Experimental Controls 
         
 
     
     Positive Controls 
  
10 
  
10 (100) 
  
10 (100) 
  
10 (100) 
 
      Negative Controls 
 
10 
  
0 (0) 
  
0 (0) 
  
0 (0) 
 
           
 
 
Study Subjects 
 
 
       
      PPH 
 
19 
  
1 (5.3) 
  
0 (0) 
  
0 (0) 
 
      Secondary PH 
 
29 
  
5 (17.2) 
  
3 (10.3) 
  
3 (10.3) 
 
      Controls 
 
150 
  
4 (2.7) 
  
2 (1.3) 
  
1 (0.7) 
 
           
 Secondary-PH Associated Condition         
• Collagen vascular 
disease 
• Congenital systemic-
to-pulmonary shunts 
• Portal hypertension 
• HIV infection 
• COPD 
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Note: Data presented as no. (%).  PPH, primary pulmonary hypertension; PH, secondary pulmonary 
hypertension; HIV, human immunodeficiency virus; COPD, chronic obstructive pulmonary disease 
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Figure Legend 
 
 
Figure 3-1.  Optical density (OD) values from patients with primary and secondary pulmonary 
hypertension and controls.  Dashed line indicates OD cut-off (0.04) for defining seropositivity. 
A total of 51 specimens (5 primary PH, 9 secondary PH and 37 controls) with OD values less 
than zero for K8.1 and ORF65 not represented.  
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3.5.  Discussion 
We found no association between KSHV and PPH.  Patients with secondary PH had 
elevated KSHV seroprevalence compared to healthy controls (10.3% vs. 0.7%); an observation 
which has been previously found among patients with secondary PH (11.8%) and blood donor 
controls (2.7%).(193)  The present findings, of no association between KSHV and PPH (0/19 
PPH patients were KSHV seropositive) are in contrast to those of Cool et al.(110) who reported 
a positive association between KSHV and PPH.  Using immunohistochemical staining (IHC) 
for LANA1, and a polymerase-chain-reaction (PCR) assay on lung DNA to detect the KSHV 
viral cyclin gene, they found 63% of PPH patients were KSHV infected.  In additional contrast, 
we observed an association between secondary PH and KSHV (P=0.01) whereas Cool et al. 
found no evidence of infection among patients with secondary PH using IHC (1 patient (6.3%) 
tested positive by PCR).  Cool et al. did not include a control group without pulmonary 
hypertension. However, using the findings from their patients with secondary PH as a 
comparison group, their data suggest the odds of KSHV infection among patients with PPH is 
increased over 23 times that of patients with secondary PH (OR=23.3, 95% CI 2.2-1082), a 
finding we could not replicate with our serological methods (OR=0, 95% CI 0.0, 3.7). 
These disparate results may have several explanations.  Some of the difference may be 
explained by different methods used to establish KSHV infection.  The techniques, PCR and 
immunohistochemistry, used by Cool et al. are prone to false-positive reactions in 
epidemiologic studies and have contributed in the past to spurious associations between KSHV 
and multiple myeloma,(360, 395) various skin cancers(352) and sarcoidosis.(129)  In their 
reported sequencing of PCR products generated from PPH lesions (see ref (110), Figure 3), all 
of the products are either too short or too long to be actual amplification products from the 
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virus and show far higher sequence variation than previously reported--indicating either the 
detection of novel herpesviruses or that some of these cases are falsely positive.  Similarly, 
special care is needed for immunostaining glandular and epithelial tissues since edge-artifact 
can be mistakenly interpreted for positivity.  It is possible that a similar problem will be 
encountered with alveolar spaces, which can be easily determined through use of blinded 
testing of tissues using appropriate control antibodies.   
Although it is conceivable that any or all of these issues played a role in the differing 
results, an alternative to our explanation, for why the present results differ from those 
previously reported, has already been put forth.  Cool et al. have suggested that KSHV 
serologic tests cannot detect organ-specific infection,(193) which we feel is particularly 
implausible given the high degree of vascularity present in the plexiform lesions characteristic 
of pulmonary hypertension, and the lack of evidence for the lung as an immunologically 
privileged site.  Furthermore, KSHV is a gamma-2 herpesvirus that is resident as a lifelong 
infection of circulating B cells.   
Our findings of no association between KSHV and PPH are robust for several reasons: 
first, the known epidemiology of KSHV is inconsistent with the known epidemiology of PPH.  
In the United States, KSHV infection is most common in HIV-infected homosexual males; 
however PPH is significantly more common among young, otherwise healthy, females.  KSHV 
is more common in Mediterranean and African populations and rare in many Asian 
populations.  One would expect the risk group, demographic and geographic distributions of 
KSHV and PPH to be similar but there is no evidence that this is the case.  Second, serological 
detection of KSHV infection has the advantage that past and current infection can be 
established irrespective of the site of infection.  In addition, properly established serological 
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assays that have been developed for KSHV since 1998 are less prone to false positive results 
than other methods such as IHC and PCR.  In fact, estimates of KSHV infection rates based on 
PCR testing among non-Kaposi’s sarcoma populations widely vary and range from less than 1 
percent to greater than 90 percent(299) and determinations of KSHV infection using IHC are 
often subjective and prone to non-specific binding which can lead to misdiagnosis of 
uninfected individuals.  Third, our study was of sufficient size to detect a significant effect of 
KSHV between patients with PPH and controls even if KSHV infection is only associated with 
one-third of patients with PPH, a rate far below that reported by Cool et al.  In sum, our 
findings of no association between KSHV infection and PPH are robust and are likely 
generalizable to patients with PPH in the United States.   
Though we found no evidence of an association between KSHV seropositivity and 
PPH, we did observe a correlation between secondary PH and KSHV infection.  This may 
reflect a causal link between KSHV and secondary PH, but it is also likely that these results 
simply reflect the high rate of KSHV infection among HIV positive individuals.  For example, 
Between 26 and 48% of homosexual men with HIV infection in the US are KSHV 
seropositive.(275, 320)  Because our study was not specifically designed to address HIV-
related secondary PH, which requires testing of appropriate HIV-positive controls, we are 
unable to distinguish among these possibilities. However, if the HIV associated cases are 
excluded from analysis, the rate of KSHV seroprevalence among the secondary PH group 
(3.7%) is remarkably similar to that observed in U.S. blood donors (3.3%)(333) and does not 
significantly differ from that observed in the controls (Fisher P=0.27) or in those with PPH 
(Fisher P=0.58).   
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In conclusion, we find no association between KSHV and PPH and that at most KSHV 
may be an uncommon contributor to secondary PH. Further, we find no association between 
KSHV and non-HIV associated secondary PH.  We are unable to exclude the possibility that 
HIV-associated pulmonary hypertension is associated with KSHV but our observations 
strongly suggest that KSHV does not play an etiologic role in PPH.  Furthermore, our findings 
support that patients with secondary PH or PPH do not have an increased susceptibility to 
KSHV infection compared to healthy controls. 
 
Addendum: Note that the serological algorithm used for this study of pulmonary 
hypertension differs from that described in chapter 2. 
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4. General Discussion 
The following section presents a discussion on the subjects of KSHV and the 
epidemiologic and clinical consequences of misclassification of KSHV infection status and the 
public health problems associated with viral infection. It is provided as background material 
not represented as part of the manuscripts or introduction presented above. 
4.1. Epidemiologic Consequences of Misclassification of KSHV Infection Status 
 Though a discussion has begun as to the importance of KSHV surveillance among 
immunocompromised hosts, the current diagnostic methods described to date have not been 
adopted for routine KSHV testing(273, 286, 296).  This is likely because of the significant 
misclassification of exposure associated with the currently available assay systems.  In a 
review by Dukers and Rezza, the authors correctly point out that in low prevalence populations 
most of the currently available assay systems would have a low positive predictive value and a 
high false positivity rate(142).  Specifically, an assay system with sensitivity of 80% and 
specificity of 99% would produce a positive predictive value of 60.6% and a false positivity 
rate of 39.4% in a population with an actual KSHV prevalence of 2.5%.   
Table 4-1 presents the effect of different assay sensitivities and specificities in low, 
medium and high KSHV prevalence populations.  These values demonstrate the potential for 
relatively high rates of false KSHV positivity in low prevalence populations with assays of low 
sensitivity. In KSHV endemic populations (KSHV prevalence of >25%) the false positive rates 
would decrease closer to acceptable levels, however for most of the developed world KSHV is 
not a ubiquitous infection.  This demonstrates that for screening of populations at increased 
risk of KSHV morbidities, but low risk of KSHV infection such as transplant donors and 
recipients, an assay with 80% sensitivity is clearly inadequate as a diagnostic tool for KSHV 
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prevention efforts.  For prevention efforts to be of greatest utility prophylactic treatments and 
enhanced clinical monitoring must be targeted to those known to be infected.  For this goal to 
be met accurate diagnosis of viral infection must be achieved. 
Table 4-1.  Variation in predictive values and false positive and negative values 
in various KS prevalence settings with different assay sensitivities 
 
Population 
Prevalence 
Assay 
Sensitivity 
 
Assay 
Specificity
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
False 
Positivity 
Rate 
False 
Negativity 
Rate 
 85% 95% 30.4 99.6 69.6 0.40
 90% 90% 18.8 99.7 81.3 0.28
2.5% 95% 85% 14 99.8 86 0.15
 95% 95% 32.8 99.9 67.2 0.13
       
       
 85% 95% 75 97.3 25 2.7
 90% 90% 61.4 98.1 38.6 1.9
15.0% 95% 85% 52.8 99 47.2 1
 95% 95% 77 99.1 23.0 0.9
       
       
 85% 95% 90.2 92.2 9.8 7.8
 90% 90% 82.9 94.4 17.1 5.6
35.0% 95% 85% 77.3 96.9 22.7 3.1
 95% 95% 91.1 97.2 8.9 2.8
       
 
Note: Predictive values calculated using Bayes theorem(164, 183, 453) where 
 
)Pr1)(1())(Pr(
))(Pr(
evalenceySpecificitevalenceySensitivit
evalenceySensitivitPVP −−+=  
 
)Pr1)(())(Pr1(
))(Pr1(1
evalenceySpecificitevalenceySensitivit
evalenceySensitivitPVN −+−
−=−  
 
4.2 KSHV Related Morbidity and Mortality as a Public Health Problem 
 In the West, among patients infected with KSHV who are immunosuppressed, the risk 
of developing Kaposi’s sarcoma is currently 20%-30%.  With a KSHV prevalence of 3%-10% 
among iatrogenically immunosuppressed patients and 20%-50% among HIV-infected 
individuals, KSHV is clearly of significant public health concern in the United States, and even 
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more so in regions with endemic rates of KSHV infection.  Of additional concern is that 
because KSHV is not screened for in the US bloods supply, an estimated 5,000 infections per 
year via blood transfusions are possible.   
It is likely that all of the KSHV-associated morbidity and mortality have not been fully 
elucidated.  For example, the risk of KSHV-related bone marrow failure after transplantation is 
not well understood and may be more common than is currently thought.  Multiple laboratories 
continue research on KSHV infection in relation to idiopathic conditions.  However, screening 
studies and long-term follow up studies using accurate KSHV detection methods will be the 
next step in fully understanding the complete extent of KSHV-associated sequelae.  
5. Summary 
 The accurate diagnosis of KSHV infection in individuals is an ongoing challenge for 
researchers.  The body of work in the preceding chapters has described the importance of 
KSHV seroassays and has illustrated the novel research techniques used to increase diagnostic 
accuracy.  Chapter 2 presented data on creating an assay algorithm which increases diagnostic 
sensitivity and specificity.  In addition the optimized algorithm was used to test KSHV 
seroprevalence among populations of clinical interest.  Article 3 continued the research and 
looked at patients suspected to be at increased risk of KSHV-associated mortality.  In sum, the 
public health importance of accurately assessing KSHV infection in populations has been 
addressed and research has been presented which describes an improved method which will 
potentially allow for a rapid and more accurate characterization of KSHV infection in 
populations who could benefit from a KSHV surveillance system. 
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